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ABSTRACT 
 
KRISTEN MARIE TAMBURRO: Profiling for KSHV and Other Herpesviruses In 
Vivo In Clinical Specimens 
(Under the direction of Dirk Dittmer) 
 
 
 The 1994 discovery of Kaposi Sarcoma-associated herpesvirus (KSHV) 
was an important finding, especially as the sharp rise in HIV infections in the 
early 1990’s led to an explosive Kaposi Sarcoma (KS) epidemic in men who have 
sex with men.  This cancer-causing herpesvirus is the causative agent of three 
diseases in addition to KS: Multicentric Castlemen Disease (MCD), Primary 
Effusion Lymphoma (PEL), and the newly described condition KSHV 
Inflammatory Cytokine Syndrome (KICS).  By understanding viral gene 
expression in human patients, we hope to better understand KSHV infection and 
its diseases, with the hope to shed light on novel therapeutic techniques. 
 In order to quantify KSHV viral gene expression, I devised methods to 
profile human clinical specimens using high-throughput qPCR.  This technique 
was used to profile microRNA expression and was published as a methods video 
journal in the Journal of Visualized Experiments (Chugh, Tamburro, and Dittmer, 
2010). The accompanying manuscript is found in the Appendix chapter. This 
same high-throughput technique was employed in Chapter II to determine KSHV 
viral load and to determine expression of viral kinases, and in Chapter III to 
determine KSHV gene expression profiles. 
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 In Chapter II, we hypothesized that HIV patients with newly diagnosed KS 
in Malawi could potentially benefit from treatment with the antiherpesviral drug 
Ganciclovir (GCV).  This was addressed through a pilot study with the AIDS 
Malignancy Consortium (AMC). By using qPCR to assess gene expression of 
two viral kinases critical to drug responsiveness, we found evidence that 78% of 
patients express a viral kinase and would potentially benefit from this therapy.  
This finding is important, as it indicates that patients can be stratified for 
treatment based on kinase expression in a tumor biopsy, which will maximize 
potential effectiveness and limit waste of drugs in a resource limited setting.  This 
work will lead to upcoming treatment studies in this population.    
Next, we used whole-genome KSHV transcriptome profiling to understand 
whether all KS patients from the Malawian cohort express similar gene 
expression profiles or if subgroups can be distinguished.  Our results indicate the 
gene expression profiles vary significantly between patients.  Specifically, two 
subpopulations were discovered- those with and those without high levels of 
genome-wide transcription.  Patients with high transcription levels demonstrated 
significantly higher CD4 counts and KSHV viremia in plasma, although HIV 
viremia, number of tumors, or size of biopsied lesion were not significantly 
associated with KSHV transcription.  This work is described in Chapter III. 
 In Chapter IV, we employed high-throughput DNA sequencing as a 
method to diagnose co-infections in an end-stage AIDS patient.  This was 
published in the Journal Virology (Tamburro et al. 2012). The patient had minimal 
KS skin lesions despite having one of the highest viral loads on record- leading to 
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the diagnosis of the newly described condition KSHV Inflammatory Cytokine 
Syndrome (KICS).  Additionally, sequencing uncovered a co-infection with 
HHV6a, which may have accounted for Systemic Inflammatory Response 
Syndrome (SIRS) that ultimately led to the patient’s death.  Notable to the 
research community, this work resulted in the first complete sequence of KSHV 
using direct methods, rather than relying on pre-sequencing cloning or cell 
passage methods.
 v 
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CHAPTER I.  
INTRODUCTION 
 
Kaposi Sarcoma (KS) 
The hungarian dermatologist Moritz Kaposi first described Kaposi 
Sarcoma (KS) in 1872 as “an idiopathic multiple pigmented sarcoma of the 
skin”(Kaposi, 1872).  These red, vascular skin lesions were described in a 
population of elderly men of Mediterranean descent, now known as the Classic 
form of KS.  Since the discovery of classic KS, three additional types of KS have 
been designated, and named based on the population of patients that they 
typically occur in: African endemic, transplant-associated iatrogenic, and AIDS-
associated (epidemic).   
KS is a mesenchymal tumor that typically begins with multifocal patch 
lesions on the skin or in the oral cavity (FIGURE 1.1 A, B).  Lesions typically 
either merge to form ulcerated plaques, or become hard solid nodular lesions 
(Ganem, 2010).  Edema surrounding the lesion and potentially involving the 
entire foot, leg, or other regions is common.  Aside from the skin, lesions of the 
oral cavity and gastrointestinal tract can occur in approximately 10% of patients 
(reviewed in (Iscovich et al., 2000)).  Involvement of organs such as spleen, liver, 
lung, and lymph node are less common in classic KS but observed in Acquired 
Immune Deficiency Syndrome (AIDS)-associated KS (reviewed in (Tappero et 
al., 1993)). 
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At the histological level, KS is very complex and is identified by long 
spindle cells forming slit-like vessels, extravasated red blood cells, and 
inflammatory infiltrate (Boshoff and Weiss, 2001) (FIGURE 1.1 C, D).  The cell 
type that spindle cells originate from is debated, as they express markers for 
endothelial cells including lymphatic markers and vascular endothelial cell 
markers, as well as that of dendritic cells, smooth muscle cells, and 
macrophages (Beckstead, Wood, and Fletcher, 1985) (Dupin et al., 1999) (Wang 
et al., 2004) (Sturzl et al., 1992).  KS tumorigenesis has been described as 
consisting of three concurrent processes- proliferation, inflammation, and 
angiogenesis (Ganem, 2010). 
 
Classic KS 
Classic KS, also known as sporadic KS, is the initially described form of 
the disease defined by Moritz Kaposi (Kaposi, 1872).  Classic KS is benign and 
slow progressing, and typically begins with patch lesions on the lower limbs.  It 
occurs most commonly in elderly men of Mediterranean and Eastern European 
Ashkenazi descent (Ross et al., 1985; Rothman, 1962) (Franceschi and Geddes, 
1995).  Other risk factors include geographic location, being over 65 years of 
age, and being of male gender.  The highest rates have been observed in the 
Italian islands of Sicily and Sardinia (Cottoni, De Marco, and Montesu, 1996) 
(Geddes et al., 1994) as well as in Greece (Touloumi et al., 1997).  Low rates of 
classic KS are reported in England, Wales, and Denmark (Grulich, Beral, and 
Swerdlow, 1992; Hjalgrim et al., 1996). Like all other forms of KS, classic KS is 
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caused by the herpesvirus Kaposi Sarcoma-associated herpesvirus (KSHV), and 
it is likely that immune dysregulation plays a role in disease pathogenesis.  
 
Endemic KS 
While classic KS is a more moderate disease mostly limited to the 
extremities, endemic of KS that occurs in Africa is highly aggressive.   Both 
adults and children suffer from KS (Ziegler and Katongole-Mbidde, 1996), and 
the prognosis is poor if untreated.  This is particularly true of the 
lymphadenopathic form of the disease, which occurs in children and involves the 
lymph nodes.  It is typically fatal within 1 year of onset (reviewed in (Iscovich et 
al., 2000)).  
KS is the most common malignancy in East African men and the third 
most common in women (Jemal et al., 2011).  Importantly, high rates of KS 
predated the AIDS epidemic in sub-Saharan Africa (Cook-Mozaffari et al., 1998).  
For this reason, the region of Africa surrounding the equator is referred to as the 
“KS Belt” (FIGURE 1.2).   
 
Potential Cofactors in Classic and African Endemic KS 
It is unclear whether geographic or genetic factors might be responsible 
for the predisposition of KS in the HIV-negative population.  Previous studies 
have indicated that there is a higher incidence of KS in areas of Italy with more 
wetlands and swamps where Malaria is endemic and bloodsucking arthropods 
are abundant (Dal Maso et al., 2005) (Geddes et al., 1995) (Ascoli et al., 2003), 
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for example on the island of Sardinia which has one of the highest rates of KS in 
Europe (Cottoni, De Marco, and Montesu, 1996).  Depletion of insects due to 
DDT and other vector-control acts resulted in a decrease in KS (Coluzzi et al., 
2003) although it is unclear if this is an effect of the decrease in malaria or in 
insect bites directly.  
Additionally, volcanic clay salts have been proposed as a potential 
cofactor for KS (reviewed in (Simonart, 2006)).  In Africa as well as in the 
volcanic region of the Mediterranean, iron bi-products are found in wet clay and 
can enter the skin through sweat glands, possibly from the feet (Price and Plant, 
1990) (Montella et al., 1996; Simonart et al., 1999).  Poverty-stricken peasants 
tend to walk barefoot and are also more likely to have KS, particularly in the 
lower extremities (Ziegler et al., 2003; Ziegler, 1993; Ziegler et al., 1997).  Iron 
also increases the risk for many cancers (Weinberg, 1996) (Huang, 2003), and it 
is possible that consuming foods and water containing high levels of iron could 
also be playing a role in the predisposition to KS in these regions (Simonart, 
2006).  
 
Iatrogenic KS 
Iatrogenic KS occurs in transplant recipients on immunosuppressant 
therapy, such as steroids (Penn, 1997; Trattner et al., 1993).  Unlike classic KS, 
males and females have approximately equal rates of iatrogenic KS (reviewed in 
(Hardy et al., 1976); Penn, 1988).  Transplant patients in the US have 
approximately a 1000-times greater risk for developing KS than the general 
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population (Penn, 1988).  Additionally, iatrogenic KS is more common in regions 
where KS is more prevalent, such as Jewish transplant recipients.  In Saudi 
Arabia, KS is the most common transplant-associated cancer (Qunibi et al., 
1988). 
Iatrogenic KS is commonly seen in renal transplant patients, and is rare in 
heart, liver, lung, or bone marrow transplant recipients (reviewed in (Iscovich et 
al., 2000)) (Gentile et al., 2005).  Lesions typically occur approximately 2 years 
after pre-transplant therapy, and the average age of onset is 42 years (Penn, 
1979) (Penn, 1988).  Although both host and donor KSHV infection has been 
proposed as the underlying cause for KS, it seems that reactivation of an 
underlying host KSHV infection in the immune suppressed setting is likely 
responsible (Becuwe et al., 2005).  High KSHV viremia in renal transplant 
patients is associated with a greater risk for developing KS (Weigert et al., 2004), 
supporting the idea that host KSHV is an important factor in developing KS.  
Tumors can regress with reduction of immune suppressants and 
restoration of the immune system (Penn, 1988) (Trattner et al., 1993) (Frances, 
1998).  Additionally, treatment with an mTOR inhibitor Rapamycin (also known as 
Sirolimus) has anti-angiogenic function (Guba et al., 2004) and has been 
effective in regression of KS (Campistol, Gutierrez-Dalmau, and Torregrosa, 
2004; Stallone et al., 2005). 
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AIDS-Associated KS 
The last but possibly most important population of people with KS is in 
AIDS patients.  15-20% of AIDS patients develop KS, and it is the most common 
cancer in this population (Beral et al., 1990; Nguyen et al., 2008) as AIDS 
patients have an approximate 3000 to 5000-fold increased risk for developing KS 
over the general population (Grulich et al., 2007; Mesri, Cesarman, and Boshoff, 
2010). 
In the 1980’s, rare diseases including KS and Pneumocystis carinii 
pneumonia (Gottlieb et al., 1981; Hymes et al., 1981), were diagnosed at an 
increased frequency in men who have sex with men (MSM) in the metropolitan 
areas of New York and San Francisco. This led to the discovery of Human 
Immunodeficiency Virus (HIV) and AIDS.  It is now understood that HIV causes a 
progressive loss of CD4+ T cells resulting in a deficient immune system that is 
unable to fight infections (Friedman-Kien, 1981; Gottlieb et al., 1981) (Masur et 
al., 1981) (reviewed in (Mildvan et al., 1982)).  KS was described as AIDS-
defining (Longo et al., 1984), and was commonly the first sign of an underlying 
HIV infection or progression to AIDS (reviewed in (Martin et al., 1998)).  Today, 
KS is still observed more frequently in AIDS patients despite being rare in the 
general population, and remains among the leading cause of death of AIDS 
patients today. In up to a third of HIV+ patients that carry KSHV, KS may reoccur 
despite successful antiretroviral therapy (ART) (Krown, Lee, and Dittmer, 2008; 
Nguyen et al., 2008).  This is an important point, as it serves as the foundation of 
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my work and justification for the continual search for novel methods of treating 
KSHV-associated disease.  
 
KSHV 
The Discovery of an Infectious Cause of KS: KSHV  
In 1994, Chang and Moore began the search for an infectious cause of 
KS, on the premise that an infectious etiology would explain the epidemic in 
immunocompromised patients, as a latent infection is able to flourish in this 
setting (Chang et al., 1994). They used Representational Difference Analysis to 
compare DNA from a KS biopsy and normal skin of the same AIDS patient, and 
discovered the herpesvirus that they named Kaposi Sarcoma-associated 
Herpesvirus (KSHV) (Chang et al., 1994) also known as Human Herpesvirus 8 
(HHV8) (Levy, 1995).  
Since its discovery, KSHV has been demonstrated to be in monocytes in 
KS biopsies by immunohistochemistry (Blasig et al., 1997), and detected in 
PBMCs, saliva, and plasma of KS patients (Carvalho et al., 2010; Humphrey et 
al., 1996; Koelle et al., 1997; Miller et al., 2006; Vieira et al., 1997), as well as in 
semen, albeit to a lesser extent (Pellett et al., 1999). Antibodies to KSHV have 
been detected in blood via enzyme-linked immunofluorescence antibody (ELISA) 
assays, western blots, and immunohistochemistry (Edelman, 2005; Tedeschi, 
Dillner, and De Paoli, 2002). Because it is identifiable in every lesion (IARC, 
1997), can be isolated from diseased individuals (Dupin et al., 1999; Sturzl et al., 
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1999), and cause disease in healthy individuals (Moore et al., 1996; Whitby et al., 
1995), KSHV is widely accepted as the causative agent of KS (Koch, 1884).  
 
KSHV Genes and Genome 
In every case where it has been examined, 100% of KS tumors are 
positive for Kaposi Sarcoma-associated Herpesvirus (KSHV, HHV8) (Chang et 
al., 1994). The KSHV genome is a linear double-stranded DNA genome of 
approximately 165kb in length.  140kb comprise approximately 87 open reading 
frames (ORFs), while the additional sequence makes up the terminal repeat 
regions that flank both ends of the viral genome (Ganem, 2010). KSHV-specific 
ORFs have been named K1 through K15, based on their location in the viral 
genome, while the remaining genes have homology to related alpha and beta 
herpesviruses. 
KSHV belongs to the subgroup gammaherpesvirus, with its closest 
human-tropic relative being Epstein-Barr Virus (EBV).   As a member of the 
herpesviridae family of viruses, KSHV can undergo both lytic and latent life 
cycles or infections.  During latency, few viral genes are expressed (FIGURE 
1.3).  The latency genes include the Latency Associated Nuclear Antigen (LANA, 
Orf73), viral cyclin homolog (v-cyclin, Orf72), viral FLICE inhibitory protein 
(vFLIP, Orf71), kaposin (K12) (Dittmer et al., 1998), and the KSHV miRNA’s (Cai 
et al., 2005; Marshall et al., 2007; Pfeffer et al., 2005).  The LANA protein 
maintains the viral episome in an inactive state, tethered to the host 
chromosome.  Reactivation results in the transcription of viral lytic genes, which 
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function to replicate the virus and modulate the host immune response (reviewed 
in (West and Damania, 2010)).  Reactivation begins with the transcription of 
KSHV immediate early genes. Viral Replication Transcriptional Activator gene 
(RTA, Orf50) is known as the “lytic switch” and is critical in initiation of the 
lytic cycle or viral replication.  RTA and other early genes can in turn 
control the expression of RTA Responsive Elements (RRE’s), either 
through directly binding the promoter or through interactions with other 
transcription factors.  RREs include the immediate early and early genes 
polyadenylated nuclear RNA (PAN RNA), ORF6, ORF21, ORF57, ORF59, 
ORF74, K1, K5, K8, K9, K12, K14, K15, and viral interleukin-6 (vIL-6) 
(Hong et al., 2011).  Expression of KSHV late genes includes viral 
structural and capsid proteins necessary for the formation of new virions.   
 
Transmission of KSHV 
The mechanism of KSHV transmission is still debated.  The discovery of 
high levels of infectious viral particles in saliva (LaDuca et al., 1998; Lampinen et 
al., 2000; Lucht et al., 1998; Vieira et al., 1997) suggests that oral shedding may 
be important in person-to-person transmission.  Related herpesviruses CMV, 
EBV, and HSV-1 can be contracted through oral transmission.  Although mother-
to-child vertical transmission may occur rarely (Brayfield et al., 2003; Gutierrez-
Ortega et al., 1989), childhood acquisition is common in low-income families 
(reviewed in (Pica and Volpi, 2007)).  Children can acquire KSHV from their 
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mothers as well as other children, particularly in regions where KSHV is endemic 
or HIV is epidemic (Bourboulia et al., 1998; Malope et al., 2007; Minhas et al., 
2008).  In Africa and regions of Europe where classic KS is observed, saliva is 
likely an important method of transmission (Gessain et al., 1999; Kasolo, 
Mpabalwani, and Gompels, 1997; Ziegler and Katongole-Mbidde, 1996). 
Sexual transmission of KSHV is controversial. KSHV can be detected in 
semen and in the female genital tract (Gupta et al., 1996; LaDuca et al., 1998; 
Whitby et al., 1999).  Studies have indicated sexual transmission is likely in MSM 
(Beral et al., 1990; Martin et al., 1998; Smith et al., 1999), but possibly less likely 
in heterosexuals (Engels et al., 2007; Smith et al., 1999) (de Sanjose et al., 
2009). 
Transfusions and blood exchange as a result of drug use also serve as 
potential means for transmission (Dodd, 2005) (Blackbourn et al., 1997) (Dollard 
et al., 2005), although the low viremia and low prevalence in the healthy adult 
population make this less of a threat than initially proposed (Engels et al., 1999; 
Pica and Volpi, 2007).  Similarly, although it is well known that transplant 
recipients often develop KS lesions, it is unclear whether this is due to 
reactivated host virus or virus from the donor organ, and both are likely (Becuwe 
et al., 2005; Razonable et al., 2005; Weigert et al., 2004).   
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Other KSHV-associated Diseases 
Primary Effusion Lymphoma (PEL) 
 Primary Effusion Lymphoma (PEL) is a body cavity-based lymphoma 
(BCBL) defined by effusion in the pleural, pericardial, or peritoneal cavities 
(Cesarman et al., 1995; Cesarman et al., 1996).  This lymphoproliferative 
disease is rare, and occurs mostly in AIDS patients but can occur in HIV-negative 
persons as well (Klepfish et al., 2001).  PEL is caused by KSHV and can occur 
with or without EBV co-infection (Arvanitakis et al., 1996) (Komanduri et al., 
1996).  Typically, PEL in HIV-negative patients is also EBV negative (Nador et 
al., 1996) (Hamoudi et al., 2004).  PEL progresses rapidly, and prognosis is 
typically poor, with median survival of 2-6 months (Komanduri et al., 1996).  
Similar to iatrogenic KS, PEL can occur in transplant recipients either alongside 
KS or alone (Dotti et al., 1999; Jones et al., 1998).  Unlike KS, PEL is monoclonal 
and derived from B cells (Reviewed in (Wen and Damania, 2010)). 
 PEL cell lines have been established, and are a useful tool in studying 
KSHV in vitro (Arvanitakis et al., 1996; Boshoff et al., 1998; Drexler et al., 1998; 
Renne et al., 1996).  PEL cell lines have high copy numbers of latent KSHV, 
typically around 40-80 copies per cell (Ablashi et al., 2002).  KSHV can be 
reactivated by treating cells with sodium butyrate (Yu et al., 1999), a protein 
kinase C-activator 12-O-tetradecanoyl phorbol-13-acetate (TPA) (Renne et al., 
1996), or the KSHV “lytic switch” gene RTA (Orf50) (Guito and Lukac, 2012; 
Lukac et al., 1998).  
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Multicentric Castleman Disease (MCD) 
 The plasma cell variant of Castleman Disease (CD), known as multicentric 
Castleman Disease (MCD) due to its presence in several lymph nodes, is 
associated with KSHV (Soulier et al., 1995).  Notably, the idiopathic localized 
hyaline vascular form of CD is more common and has not been associated with 
KSHV infection (Ablashi et al., 2002; Cronin and Warnke, 2009).  MCD is a rare 
condition that arises mostly in HIV-positive immune suppressed patients, and 
less commonly in HIV-negative persons who are immunocompromised 
(Polizzotto et al., 2012b).  The prognosis for MCD patients is poor, and median 
survival is approximately 2 years (reviewed in (Stebbing et al., 2008)) 
(Oksenhendler et al., 2000).  MCD is characterized by severe flares of symptoms 
including fever, night sweats, malaise, splenomegaly, anemia, thrombocytopenia, 
fatigue, edema, high KSHV viral loads and elevated inflammatory markers 
(Polizzotto et al., 2012a) (Oksenhendler et al., 1996) (Menke, Camoriano, and 
Banks, 1992).   
Diagnosis of MCD is dependent on immunohistochemical staining of a 
lymph node biopsy (Oksenhendler et al., 1996) (Du et al., 2001).  MCD is also 
called multicentric angiofollicular hyperplasia due to its characteristic 
immunohistochemical appearance of germinal center vascular proliferation.  The 
lymph node architecture is generally maintained, however the germinal center is 
typically hypocellular and the interfollicular region is proliferated (Chadburn et al., 
2008) (Schmidt et al., 2008).  KSHV-positive polyclonal IgM lambda cells are 
evident (Du et al., 2001) (Hassman, Ellison, and Kedes, 2011) and high levels of 
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viral interleukin-6 (vIL6) are expressed.  Despite sharing molecular similarity of 
approximately 25% (Neipel et al., 1997), vIL6 differs from its human homolog in 
its ability to bind to the gp130 subunit directly without requiring the high affinity 
IL6 receptor gp80 subunit (Molden et al., 1997).  This results in an increased 
activiy for vIL6, which may contribute to the high levels of inflammation 
responsible for symptoms in MCD patients (reviewed in (Sin and Dittmer, 2012)). 
 
 
KSHV Inflammatory Cytokine Syndrome (KICS) 
 KSHV Inflammatory Cytokine Syndrome (KICS) is a KSHV-associated 
systemic inflammatory disease that has only been recently described (Uldrick et 
al., 2010a).  To date, only 4 publications exist on KICS- one of which is our case 
study described in Chapter 4. The initial report describes a retrospective review 
of six HIV-positive, KSHV-positive patients with a disease that symptomatically 
mimics MCD, despite no pathological evidence of MCD (Uldrick et al., 2010b).  
Symptoms included fevers, wasting, edema, anemia, thrombocytopenia, elevated 
inflammatory markers, adenopathy, and splenomegaly, however MCD was 
excluded after multiple attempts to confirm with lymph node biopsies. MCD was 
not found in follow-up or autopsy, and symptoms were attributed to high levels of 
IL6 and vIL6 production.  Patients with KICS also had high KSHV load, 
comparable to MCD patients, but significantly less than KS patients.  Another 
study found that KICS patients and MCD patients have more single nucleotide 
polymorphisms (SNPs) in KSHV microRNAs (miRNA) than KS patients (Ray et 
al., 2012).  Our group reported a case study of a KICS patient with HHV6 co-
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infection, although it is unknown whether this co-infection is correlated with KICS 
or if this was unique to this patient (Tamburro et al., 2012). 
A working definition of KICS diagnosis was characterized as having 
indicators from at least 2 of these categories- Symptoms, Laboratory 
abnormalities, and Radiographic abnormalities- along with elevated C-reactive 
protein, elevated KSHV load in PBMCs, and the exclusion of MCD by 
pathological evaluation (Polizzotto et al., 2012b). 
 As this disease is currently poorly understood, treatment options are 
unclear, although it is possible that patients may respond to antiviral drugs such 
as Ganciclovir alone or in combination with Zidovudine, or Rituximab and 
liposomal doxorubicin as these drugs have had some success in treating MCD 
and KS (Cianfrocca et al., 2010; Northfelt et al., 1998; Polizzotto et al., 2012a; 
Uldrick et al., 2011; Uldrick et al., 2010a). 
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TABLES AND FIGURES 
FIGURE 1.1: Kaposi Sarcoma lesions and histology 
 
 
 
 
 
 
 
 
(A) Gross lesions of KS on the palate of a patient with AIDS. (B) Nodular skin 
lesion seen in KS. (C) Histopathology of a nodular KS lesion, showing fascicles 
of elongated spindle cells and numerous slit-like neovascular spaces. (D) High-
power image of KS spindle cells. All images reproduced from the CDC’s open-
access Public Health Image Library.  (Ganem, 2010). 
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FIGURE 1.2: KS Belt in Africa 
 
 
 
 
Cumulative incidence from birth to age 64 years of endemic (non-HIV-related) 
Kaposi’ sarcoma among men in Africa. Estimates are from Cook-Mozaffari et al. 
(Cook-Mozaffari et al., 1998).  (Dollard et al., 2005) 
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FIGURE 1.3: KSHV Genome 
 
 
 
 
Structure of the KSHV (HHV-8) genome. The central portion of the genome is 
flanked by the terminal repeats, labeled TR. The KSHV genome contains close to 
100 open reading frames. Many of these are conserved in most herpesviruses; 
these are present in the conserved blocks (white boxes) and are not indicated. 
Other open reading frames are unique to rhadinoviruses, gammaherpesviruses, 
or KSHV and are present in more divergent areas of the genome (indicated by 
gray boxes). ORFs that have homology with herpesvirus saimiri are assigned the 
corresponding numbers, and ORFs without recognizable homologues were 
numbered separately and given the prefix K (K1 to K15) (Ablashi et al., 2002).   
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CHAPTER II: 
ART NAÏVE KAPOSI SARCOMA (KS) PATIENTS EXPRESS KSHV 
ORF21 AND ORF36 AND MAY BENEFIT FROM GANCICLOVIR 
THERAPY– AN AIDS MALIGNANCY CONSORTIUM STUDY  
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INTRODUCTION 
Globally Kaposi sarcoma (KS) is the most common malignancy associated 
with HIV infection (Jemal et al., 2011). The clinical course of KS can range from 
an indolent disease to a severe, progressive disease leading to significant 
morbidity and mortality. Advances have been made in the treatment of KS 
(reviewed in (Dittmer, Richards, and Damania, 2012; Krown, 2011)). However, 
optimal therapy and long term management have not been defined. Standard 
chemotherapy (Doxil™) is non-curative and limited by the cumulative lifetime 
dose of doxorubicin and its derivatives. Combination Antiretroviral therapy 
(cART) for HIV is essential for HIV-infected KS patients but despite successful 
cART, up to a third of KS patients have disease recurrence (Krown, Lee, and 
Dittmer, 2008; Nguyen et al., 2008) or do not respond to ART alone. Hence, 
additional treatment options are needed. 
KS is a spindle cell tumor of endothelial cell lineage, which is 
characterized histologically by slit-like neovascular spaces, extravasated red 
blood cells, and an infiltrate of lymphocytes or other inflammatory cells. The 
discovery of KSHV was a major advance in our understanding of the disease 
(Chang et al., 1994) as essentially all cases of KS carry KSHV. KSHV is a human 
gamma herpesvirus that encodes approximately 80 proteins that mediate viral 
replication and virus-host interactions. Theoretically all gamma herpes virus-
associated tumors contain well-defined therapeutic targets, namely the viral 
proteins. These are only expressed in the tumor cells, but not uninfected normal 
cells. The viral thymidine kinase, open reading frame (orf) 21, and a second 
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protein with kinase activity, orf36, represent examples. They could convert anti-
herpesvirus drugs such as ganciclovir into their functional, toxic forms, which at 
high concentrations inhibit tumor cell growth as well as viral replication (Davis et 
al., 2007; Feng et al., 2002; Fu et al., 2008; Kurokawa et al., 2005). The clinical 
experience of anti-herpesvirus drugs in KS has yielded mixed results, in part 
because patients were enrolled without knowing if their lesions expressed the 
drug activator (Krown, Dittmer, and Cesarman, 2011; Little et al., 2003; 
Pantanowitz et al., 2008; Uldrick et al., 2011). 
AIDS-KS lesions vary significantly in their degree of KSHV gene 
expression, including orf21 and orf36 expression, allowing division of AIDS KS 
cases according to the degree of so-called “lytic” gene expression.  Such 
biologic-based division may be useful in optimizing treatment for KS patients.  
Previous studies evaluating this principle were small, and most included patients 
that were heavily pre-treated with chemotherapy, ART or both(Dittmer, 2003; 
Dittmer, 2011). To expand our understanding of KSHV gene expression in 
resource limited settings, we conducted a cross-sectional study in seventy ART 
treatment naïve KS patients attending our clinic in Lilongwe, Malawi. We 
measured the KSHV mRNA expression and KSHV viral load, and evaluated 
associations between these parameters and clinical factors so as to develop 
potential novel stratification methods that may provide prognostic information.   
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METHODS 
Study Setting:  The Lighthouse (LH) ART clinic at Kamuzu Central Hospital 
serves as the Centre of Excellence for the Central Region of Malawi.  In addition 
to providing primary care and general ART services for 20,000 ART clients 
according to Malawi ART guidelines, the Lighthouse provides specialized 
services for referred cases including combination chemotherapy 
(Bleomycin/Vincristine) for Kaposi Sarcoma, evaluation of severe toxicities and 
ART treatment failure, and modification of ART for second line and non-standard 
regimens.  All services at the Lighthouse Clinic are provided for free. 
 
Design:  Cross-Sectional Study 
 
Participants:  All adult (age ≥ 18 years) KS patients presenting to the LH clinic 
between Nov. 2008 and Aug. 2010 were evaluated for potential enrollment.  
Patients with prior chemotherapy or antiretroviral therapy use were excluded, as 
were individuals with disease limited to the oral cavity (due to inability to safely 
biopsy such lesions in the clinical setting).    
 
Clinical Procedures: KS clinical staging was performed according to ACTG 
criteria (T1 advanced stage vs. T0 limited disease), blood was obtained for CD4 
cell count and KSHV quantification and punch biopsy was performed for 
evaluation of KSHV gene expression.  The 2x2 mm tumor punch biopsy samples 
were immersed in RNAlater due to its suitability for collection at the bedside, 
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local storage, intercontinental transport (samples could be shipped at room 
temperature) and transcription profiling   
 
Laboratory Procedures:  CD4 counts and HIV RNA copies/mL was performed 
in real time at the UNC Project laboratory using FACSCOUNT and Roche 
Amplicor assay 1.5.  KSHV viral load was determined from plasma by real-time 
qPCR as described (Jacobson et al., 2009) using primers LANA78 (5’-
ggaagagcccataatcttgc and 5’-gcctcatacgaactccaggt), and SYBRgreen™ as the 
method of detection. 
KSHV mRNA levels were determined in batch at the UNC-Chapel Hill Vironomics 
Core as per our published procedures (Papin et al., 2005). In short, RNA was 
isolated by RNAzol™, reversed transcribed using random hexamers, and 
subjected to real-time qPCR using primers specific for KSHV latent mRNAs and 
multiple primer pairs specific for the viral kinases orf21 (thymidine kinase) and 
orf36 (phosphorylase). The primers were: Orf21: (pair 1: 5’-cctcattagaacgcctgtga, 
5’-cgccttaccagacttcatca; pair 2: 5’-ctctcatgcacctgaagca, 5’-ataagcccacgccaattct; 
pair 3: 5’-gtgatcgagctttgcttttg, 5’-gaccctgcatgtctcctcta; pair 4: 5’-
cgtcccttcctccattctg, 5’- gcccagctctatgttggtaca; pair 5: 5’-ggacatacacacggtcctca, 
5’-gctggatgcaaatcgtacc; pair 6: 5’-cactctcgaacgctgttgtc, 5’-atcgctctcatcgtagctca), 
Orf36: (pair 1: 5’-ggtcaacctgagtgtcatgg, 5’-ttagtccacttgctcccaga; pair 3: 5’-
acctggggtttaagcaacac, 5’-caggcatgtcagcagagtg), Latency transcript: (pair 1: 5’-
ctcccaacacctggactttt, 5’-aaacatcgcatcccaatatg; pair 2: 5’-aagcaggtgtccaaagaaca, 
5’-cgtcgctaagactgcctct; pair 3: 5’-tcccacgctatgtgaggat, 5’-ccaaaagattaagggccaac; 
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pair 4: 5’-cagaccagtcgcccataac, 5’-tcatttcctgtggagagtcc; pair 5: 5’-
cagtagcccaccaggagata, 5’-tagctttcgcaggacaatca).  The mRNA levels for gapdh, 
actin and hprt were determined and used to ascertain mRNA quality. Real-time 
qPCR yields so-called CT values, which represent log2-transformed measures of 
mRNA abundance in the sample. These were used in the statistical analysis. 
 
Statistical Analysis:  We performed basic descriptive statistics with bivariate 
comparisons according to ACTG Tumor status using Chi2 methodology and 
Student’s t-test as appropriate. We used Shapiro-Wilk test to evaluate if 
individual data groups were normal distributed. We determined the proportion of 
patients who demonstrated evidence of orf21 or orf36 transcription, and KSHV 
viral load. The Wilcoxon signed rank test was used to evaluate changes in KSHV 
viral load between samples for individual genes, Pearson regression analysis to 
establish a correlation between viral loads, CD4 counts and viral mRNA levels 
and unsupervised mixed factor analysis to evaluate overall gene expression 
patterns. Further statistical analysis was performed using R version 2.15.1. 
Principal component analysis and agglomerative Hierarchical Clustering using 
Ward’s algorithm was conducted as published by Husson et al. (Husson, Le, and 
Pages, 2011). Tree based regression was used as implemented in the R rpart 
function and previously described (O'Hara et al., 2009). Fisher’s exact test or 
ANOVA was used to evaluate if a particular clinical variable or the expression of 
the KSHV kinase was over represented in any one of the clusters. 
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Ethics: The study was IRB approved in Malawi by the National Health Sciences 
Review Committee and at UNC (IRB# 08-0567) as  "AMC-S001: CID 0802 - A 
Pilot Study of Kaposi Sarcoma associated Herpesvirus (KSHV) Gene Expression 
in Patients with Newly Diagnosed Kaposi Sarcoma (KS) in Malawi“. All subjects 
provided written informed consent. 
 
RESULTS  
Study Population 
From Nov 2008 through Aug 2010, we screened 217 HIV infected KS 
patients. 70 (32%) of the screened patients were enrolled.  Primary reasons for 
exclusion included previous use of ART (26%), chemotherapy (9.5%), or both 
(48%), and disease restricted to oral cavity (5.5%); the remaining 11% of patients 
were excluded for other reasons. In total, 147 patients were excluded. Among 
enrolled patients, 71% were male and median (Interquartile range) age, BMI, 
CD4 and HIV RNA were 32 years (IQR 29-38), 22.4kg/m2  (20.5-24.3), 181 
cells/mm3 (85-261) and 138,641 copies/ml (54,900-285,000), respectively (Table 
3.1). 81% presented with T1 (poor risk) KS. 15 (22%) patients had 1 -10 KS 
lesions, 42 (60%) patients had 10 – 50 lesions, and 12 (17%) patients had over 
50 lesions. 32 (46%) patient had edema, 6 (9%) concurrent oral KS, and 4(6%) 
evidence of visceral KS (in the absence of CT scan, we cannot exclude that more 
of the patients had visceral KS).  
We observed no correlation between log HIV viral load and CD4 counts 
per microliter overall (Figure 2.1A).  Only after we restricted the analysis to 
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individuals with CD4 counts < 500 cells/mm3, we observed a weak linear inverse 
correlation between 10log HIV VL and square root CD4 (drop of 54 ±25 CD4 cells 
/ µl per log2 HIV RNA step, Spearman’s r = -0.205), consistent with the earlier 
studies in the US (Mellors et al., 2007; Mellors et al., 1996). 
 
KSHV viral load does not correlate with CD4 count or HIV viral load. 
We determined KSHV viral load in plasma (Figure 2.1B). We chose cell-
free KSHV rather than KSHV DNA in PBMC, as this would be more directly 
related to viral replication and exclude KSHV-positive circulating KS tumor cells. 
Median plasma KSHV DNA viral load was 3.36 log copies (IQR: 2.87-3.75), with 
no significant association of log KSHV viral load to disease stage (T0 vs. T1) or 
other clinical parameters by multivariate linear regression (data not shown). In 
7/66 (11%) samples, KSHV viremia was below our detectable limit (200 
copies/ml), even though we could detect KSHV in skin biopsies in 6 of these 7 
patients. We were able to amplify the internal control in these samples, thus they 
represent cases of KS with no detectable systemic viral load.   
After excluding these 7 samples with KSHV viral load below the limit of 
detection (200 copies/ml), log10(KSHV DNA) was normally distributed. (Figure 
2.1C, 2.1D).  As CD4 count was not normally distributed, (Figure 2.1E) we used 
square-root-transformed CD4 counts for all subsequent analyses as introduced 
by Mellors et al.(Mellors et al., 1996). We observed no correlation between log 
KSHV viral load and log HIV viral load, or between log KSHV viral load and 
square-root-transformed CD4 count (data not shown). This suggests that these 
 41 
three laboratory values are independent and in combination may be useful for the 
purpose of patient classification. 
 
KSHV latent mRNAs are detectable in KS biopsies. 
We set out to determine whether molecular detection of KSHV 
transcription in a suspected lesion was feasible, and to evaluate whether 
RNAlater is a suitable fixation and transport medium for samples obtained from 
resource limiting settings. For 5/66 (8%) biopsies, the “housekeeping” mRNA 
exhibited abnormally low levels (CT > 32), suggestive of RNA degradation.  
These samples were excluded from further analysis.  We could not detect the 
mRNA for the KSHV latent genes such as the latency associated nuclear antigen 
(LANA) in 10 KS biopsies for which we could quantify the reference genes at 
average mRNA levels. This suggests that the RNA quality was appropriate, but 
that very few cells in the lesions were infected or that the level of latent gene 
expression per cell was minimal.  With the exception of one, these 10 patients 
had nevertheless detectable KSHV viral load in plasma. The ten samples from 
which latency genes were not detected were excluded from further analysis. 
 
KSHV kinase mRNAs are detectable in KS lesions.    
KSHV lytic mRNA  (either orf21 or orf36 or both) was detectable in 40/51 
(78%) of biopsies with substantial levels of KSHV latent mRNA.  In each case the 
mRNA levels for orf21 or orf36 were outside the linear range of our assay. This 
suggests that either these mRNAs were expressed at very low levels or by very 
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few cells within the KS lesion. For further analysis we computed a kinase score: 
0, no KSHV kinase mRNA was detected; 1, either orf21 (1a) or orf36 (1b) mRNA 
were detected; 2, both orf21 and orf36 were detected.  11/51 (22%) had a kinase 
score of 0, 23/51 (45%) a kinase score of 1, and 17/51 (33%) a kinase score of 2.  
Next, we explored whether kinase score was correlated with other 
variables. First, we used a multivariate analysis on a multinomial regression 
model.  Kinase score was not correlated with any of the other variables (tumor 
stage, edema, age, gender, weight loss, weight, height, temperature, pulse, 
respiration, lymph node involvement, oral lesions, visceral lesions, CD4 count, 
log HIV viral load, Karnovsky performance status, BMI or log KSHV viral load.   
As an alternative approach, we used principal component analysis (PCA) 
followed by unsupervised clustering based on the principal components as 
described (Husson, Le, and Pages, 2011), to test for the presence of different 
classes of KS patients on the basis of HIV viral load, KSHV viral load, and CD4 
cell count measurements. The first two components of the PCA accounted for 71 
% of the variation. The HIV load and CD4 count were being almost orthogonal to 
each other (Figure 2.2A). This is consistent with the absence of any correlation 
between these two measures.  
A 2D PCA plot was generated, stratifying patients based on the HIV viral 
load and KSHV viral load (Figure 2.2B). This led to two classification rules that 
associate the kinase score within a lesion to HIV viral load and KSHV viral load. 
We could not improve the result by including CD4 count or any other clinical 
parameter into the model (data not shown).  Patients were color-coded according 
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to their kinase expression profile; 0- no kinase expression, in black; 1- orf21 or 
orf36 only, in red; and 2- expression of both orf21 and orf36, in green.  No 
distinct clusters were evident based on these 2 components, indicating kinase 
expression profiles were distinct from these components. Patients who had the 
highest kinase score within a KS biopsy tended to have logHIV viral load > 4.7 
and patients with the lowest kinase score within a KS biopsy tended to have 
logHIV viral load < 4.7, i.e. low and logKSHV viral load < 4.1 (including non 
detectable VL).  However, numerous patients were classified incorrectly by using 
only these two parameters, suggesting that viral kinase expression is primarily 
driven by local factors, specific to the microenvironment of each particular lesion. 
As an alternative approach with a greater ability to detect non-linear 
associations, we employed tree-based regression (Figure 2.2C).  We then used 
Fisher’s exact test and ANOVA to evaluate if a particular clinical variable or the 
expression of the KSHV kinase was overrepresented in any one of the clusters. 
None of the clusters was enriched for a particular clinical marker. As in figure 
2.2B, kinase score was again coded at the base of the tree to visually determine 
if any cluster was enriched for a specific kinase profile. The kinase score (p≤ 
0.039) and Orf21 expression (p≤ 0.0022) differed significantly among the 
different clusters, orf36 expression did not differ significantly among the different 
groups. As seen in figure 2C patients with a kinase score of 2 (green), indicating 
the presence of both kinases in the lesions, tended to be enriched in the right 
cluster and those with a kinase score of 0 (black) tended to be enriched in the left 
cluster. We interpret this result to mean that there exists two populations of KS 
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patients and that this observation may be developed into a useful measure to 
direct treatment. 
 
DISCUSSION 
 For KS patients with HIV infection, cART represents first line therapy as 
cART alone can lead to the resolution of KS in some patients (Borok et al., 2010; 
Dupont et al., 2000; Gill et al., 2002; Murdaca et al., 2002; Tam et al., 2002). It is 
unclear, however, which KS patients respond to ART alone and why(Borok et al., 
2010; Mosam et al., 2012; Nguyen et al., 2008).  ACTG KS staging based on 
immune status, KS disease stage and systemic disease provided prognostic 
information in the pre-ART era (Johnston et al., 2009), but in the ART era, CD4 
count may no longer provide prognostic information (Nasti et al., 2003).  This 
represents a gap in our understanding of this disease and its clinical 
management.  Using biologically derived factors related to KSHV potentially may 
prove useful for prognosis and treatment stratification. We previously 
demonstrated that AIDS-KS lesions differ significantly in their degree of KSHV 
gene expression, including orf21 and orf36 expression. We could classify AIDS 
KS from the pre-ART era and AIDS KS that developed in ART-suppressed 
individuals into two groups based on the overall degree of so-called “lytic” gene 
expression (Dittmer, 2003; Dittmer, 2011).  We hypothesized that systemic KSHV 
viral load and KSHV mRNA detection within a KS biopsy could be used in 
addition to clinical staging and HIV load to stratify KS patients for therapy and 
that a subset of KS patients, would express the viral thymdine kinase orf21 or the 
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viral phosphorylase orf36, and thus may benefit from adjunctive anti-herpesviral 
therapy (in addition to ART alone or in addition to ART + chemotherapy). 
We find that 78% of KS patients expressed the KSHV thymidine kinase 
orf21 or the KSHV phosphorylase orf36 such that a kinase score quantification 
can be constructed.  Additionally, using CD4, HIVRNA, and KSHV RNA, specific 
categories of patients can be defined, potentially with prognostic value. 
Using a combination of HIV viral load, KSHV viral load and CD4 counts at 
presentation we found evidence for four distinct groups or clusters of KS patients 
(Figure 2.2C). KSHV orf21 kinase expression in the biopsied lesions was 
enriched in one group compared to the others. KSHV orf36 phosphorylase 
expression was observed in each of the groups. By comparison to the high 
number (78%) of lesions with evidence of kinase expression in ART naïve KS in 
this endemic area, only 1 of 8 (13%) of KS lesions that were studied in HIV-
suppressed patients on ART in the US showed evidence of lytic KSHV gene 
expression (Dittmer, 2011). Evidence of KS kinase transcription was even rarer 
in classic KS, where ganciclovir monotherapy did not induce KS regression 
(Krown, Dittmer, and Cesarman, 2011). This suggests that ART naive KS 
patients may benefit from anti-herpesviral therapy in addition to ART and/or anti-
cancer therapy and that these benefits would be most pronounced if patients 
were stratified based on intralesional demonstration of KSHV kinase expression. 
We observed only a minimal correlation between KSHV viral load, HIV 
viral load and CD4 counts (Figure 2.1).  This is consistent with historical data in 
the US and more recent studies in Africa that show associations at varying 
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degrees, with some limited (Johnston et al., 2009; Maskew et al., 2011; Mellors 
et al., 2007; Mellors et al., 1996) and others more pronounced. One difference 
with this study compared to earlier work is that previously KS was not used as 
the sole inclusion criterion, but all AIDS defining conditions, including other 
infectious complications were.  KS is typically thought as the first indication of 
AIDS. During the early stages of the US HIV epidemic, KS was observed in HIV-
positive individuals with the highest CD4 counts. By contrast CMV viremia, 
histoplasmosis and systemic microbial infections trend with very low CD counts 
in populations with no endemic KS and low KSHV seropositivity (Hanson et al., 
1995; Mocroft et al., 2009).  
An implication of this study is that in KS-endemic areas, HIV-associated 
KS disease occurs in the setting of high CD4 counts (> 200), as does KSHV viral 
loads. Cases of KS despite high CD4 counts were also seen in an ART-naïve 
South African cohort (Cassol et al., 2005) as well as in a recent study in Uganda 
(Johnston et al., 2009). Even though our patients had relatively high levels of 
CD4 cells, their immune system was not able to control HIV replication, KSHV 
replication or KS disease. It will be interesting to see whether initiating ART in 
individuals with CD4 ≤ 350 as recommended (Misiri et al., 2012) will prevent KS 
cases in endemic areas. In the post-ART era approximately 30% of KS in the US 
manifested itself in long-term ART controlled individuals (Cianfrocca et al., 2010; 
Krown, Lee, and Dittmer, 2008; Maurer, Ponte, and Leslie, 2007) with no 
detectable HIV viral load and CD4 > 250.  In this setting KS is typically mild (T0), 
with few flat lesions that are localized to the peripheral extremities. By contrast 
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the KS that we observed in African patients with CD4 > 250 and not on ART and 
with substantial HIV viral loads was extensive (no association between lesion 
count and CD4 count) and aggressive. 
The diagnosis of KS is a challenge in areas where routine and timely 
pathology is limited. A molecular assay analogous to HIV viral load testing would 
greatly improve diagnosis. Our experience suggests that KSHV viral load 
detection in blood has rather limited sensitivity. We observed 7 cases of KS with 
no detectable systemic KSHV viral load. For 6 of these patients the KS lesions 
were positive for KSHV mRNA, indicating that neither the lesions, nor any other 
reservoirs released KSHV into the blood stream to a detectable level. Another 
study also failed to detect KSHV viral load in 25% of KS patients (Martin-
Carbonero et al., 2008). Thus detecting KSHV in lesions rather than in blood may 
have superior sensitivity, since KSHV latent mRNAs are present in every KS 
tumor cell and every KS lesion (Dittmer, 2003; Dittmer, 2011).  As formal 
pathology expertise is typically not available in resource – limited settings, FNA-
based detection of KSHV mRNAs may improve diagnosis. An analogous assay 
based on high-risk HPV E6/E7 mRNA detection in cervical swabs (Aptima) is 
currently being introduced and exhibits greater specificity for cancer than high 
risk HPV DNA-based viral load assays (Ratnam et al., 2011). The advantages of 
these types of molecular assay in resource-limited settings, particularly if it can 
be developed as a robust point-of-care assay, are that they obviate the need for 
expensive pathology infrastructure and for evaluation by pathologists. 
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SUMMARY 
Overall, we have demonstrated that KSHV mRNA expression varies among KS 
patients and may provide a basis for stratification for prognosis or potentially 
novel anti-viral treatment strategies.  Prospective evaluation of treatment 
response to chemotherapy, such as upcoming randomized phase III clinical trials 
ACTG/AMC 5263 and 5264, will provide additional information on the utility of 
KSHV-derived factors such as KSHV viral load and KSHV gene expression on 
prognosis and treatment response. 
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TABLES AND FIGURES 
 
TABLE 2.1: Cohort Characteristics (N=70, unless noted) of Kaposi 
sarcoma patients evaluated at Lighthouse ART clinic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†2 samples lost in transit, 2 failed to amplify the internal control 
Category Mean 
Age in years 33 ± 6.6 
Male gender 50 (71%) 
Karnofsky score > 70 59 (84%) 
    
CD4 cells / µl  206 ± 160 
CD4 < 200 40 (57%) 
HIV copies/ ml (n=66)†  193,229 ± 188,916 
KSHV* copies / ml 5,124 ± 9,580 
Orf36 detectable 34 (59%) 
    
No. of KS lesions   
1 - 10 15 (22%) 
10 - 50 42 (60%) 
>= 50 12 (17%) 
    
Edema 32 (46%) 
Oral KS 6 (9%) 
Visceral KS 4 (6%) 
 50 
FIGURE 2.1: Lack of correlations between KSHV viral load, CD4 count and 
HIV viral load in ART naïve patients presenting with HIV-associated KS in 
an endemic KSHV area.  
 
 
(A) Scatterplot of log10 HIV viral load (in copies per ml) on the vertical axis 
versus CD4 cell count per microliter on the horizontal axis. The solid red line 
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indicates a linear regression taking into account only data points with CD4 < 550. 
The blue striped lines indicate the cutoff levels of CD4 counts used in panel B. 
(B) Scatterplot of log10 KSHV viral load (in copies per ml) on the vertical axis 
versus log10 HIV viral load (in copies per ml) on the horizontal axis. The symbols 
are coded by CD4 group as indicated above the panel. The black striped lines 
indicate the limit of detection for KSHV (200 copies /ml) and a cut-off for low HIV 
viral load (4.4 log10 copies /ml). The HIV viral load assay had a limit of detection 
of 50 copies / ml). (C) QQplot of log HIV copies/ml distribution. Theoretical 
quantiles are shown on the horizontal, samples quantiles on the vertical axis. 
Vertical blue bars on the inner vertical axis represent the distribution histogram, 
yellow highlight the region designated low HIV load (low). (D) QQplot of log 
KSHV copies/ml distribution. Yellow highlight the region designated non-
detectable KSHV in plasma (nd). (E) QQplot of CD4 count / µl distribution. Note 
the curvature of the points, which denotes systematic difference from a normal 
distribution (p≤0.05 by Shapiro-Wilk test). 
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FIGURE 2.2: Evidence for different types of KS.  
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(A) Correlation of the variables across the first two principal components (Dim 1 
on the horizontal and Dim 2 on the vertical axis). Black arrows denote the 
variables used for calculation of the principal components, blue arrows show 
supplemental variables not used for PCA. Perpendicular arrows represent un-
correlated variables (logHIV and sqrt(CD4), parallel arrows represent are 
perfectly correlated variables. Opposite direction indicates negative correlation. 
(B) Representation of patients in the first two PCA dimensions. Green indicates 
patients with detectable orf36 and orf21 mRNA in the lesion, black indicates 
patients with no detectable orf36 and orf21 mRNA in the lesion, and red indicates 
the intermediate group, which we can detect either orf21 or orf36 mRNA. (C) 
Shown is the hierarchical tree representation of KS cases after unsupervised 
clustering based on PCA. The patients clustered into four distinct groups. The 
vertical axis indicates the inertia gain (or fraction of explained variation). Kinase 
score for each patient is indicated at the tree base; 0- no kinase expression, in 
black; 1- orf21 only or orf36 only, in red; and 2- expression of both orf21 and 
orf36, in green. 
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CHAPTER III: 
VARIATION IN GENE EXPRESSION PROFILE DISTINGUISHES 
SUBTYPES OF KAPOSI SARCOMA TUMORS 
 
 
PREFACE 
 This work is being prepared for submission2.  This study is an extension of 
the AIDS Malignancy Consortium study described in Chapter 2 (AMC- S001).  As 
in that project, Mina Hosseinipour and Dirk Dittmer designed the study along with 
Jeanette Lee and other members of the AIDS Malignancy Consortium.  I 
performed all experiments, analyzed the data, made tables and figures and 
drafted the manuscript.  Jie Xiong assisted with statistical analysis. The 
remaining authors played similar roles as described in Chapter 2. 
 
 
 
 
 
 
 
 
 
_______________________________________ 
2 Manuscript in preparation- Tamburro, K.M., Hosseinipour, M.C., Xiong, J., 
Namarika, D., Nyirenda, M., Mwafongo, A., Chiwoko, L., Kamwendo, D., Hoffman, I., 
Lee, J., Phiri, S., Dittmer, D.P.  Variation in Gene Expression Profile Distinguishes 
Subtypes of Kaposi Sarcoma Tumors. 
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INTRODUCTION: 
Kaposi Sarcoma (KS) is the most common malignancy in East African 
men and the third most common in women in the region (Bray et al., 2013; de 
Martel et al., 2012; Jemal et al., 2011; Jemal et al., 2012; Soerjomataram et al., 
2012).  This is at least partially reflective of the high prevalence of AIDS in this 
region, which is at an estimated 11% of the population in Malawi (UNAIDS.org), 
as KS is commonly diagnostic of AIDS and/or HIV progression (Martin et al., 
1998).  KS is also endemic in this region with an estimated KSHV sero-
prevalence in excess of 50%, contributing to the high prevalence of KS in the 
HIV+ population as well as the general population (Malope-Kgokong et al., 2010; 
Newton et al., 2006; Wakeham et al., 2011).  
Nearly all KS tumors are positive for Kaposi Sarcoma-associated 
Herpesvirus (KSHV, HHV8) (Chang et al., 1994; Martin et al., 1998).  Presumed 
KSHV negative cases of KS are often classified on the basis of histological 
analysis alone. In these cases it is not clear if the molecular assay for the 
presence of KSHV failed or if the diagnosis was incorrect. To date, most 
diagnoses of KS include the demonstration of KSHV LANA protein expression 
within the spindle cells of the lesion.  
As a member of the herpesviridae family of viruses, KSHV can undergo 
both lytic and latent life cycles.  During latency, few viral genes are expressed, 
including the Latency Associated Nuclear Antigen (LANA), viral cyclin homolog 
(v-cyclin) and viral FLICE inhibitory protein (vFLIP) (Dittmer et al., 1998).  
Reactivation results in the transcription of viral lytic genes, which function to 
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replicate the virus and modulate the host immune response (reviewed in (West 
and Damania, 2010)). 
In this study, we profiled gene expression of all predicted lytic and latent 
KSHV genes from 62 tumor biopsies from treatment naïve HIV-positive KS 
patients in Malawi.  Previous studies have described KSHV gene expression 
profiles in KSHV positive pleural effusion lymphoma (PEL) cell lines (Fakhari and 
Dittmer, 2002; Jenner et al., 2001; Jenner et al., 2003; Sarid et al., 1998), and 
also have compared transcription profiles in KS biopsies from patients in the pre- 
and post-HAART era (Dittmer, 2011)(Dittmer, 2003).  This study is the first to 
profile KS tumor gene expression in untreated KS in an HIV-positive population 
in a KSHV-endemic area. The overall aim of the study was to identify distinct 
subpopulations of KS on the basis of differential viral gene expression.  This 
approach follows the paradigm established in other research areas that has 
shown distinctive subtypes of breast cancer and lung squamous cell carcinoma 
based on host gene expression patterns.  These subtypes have been used to 
stratify treatment and gauge outcome (Perou et al., 1999; Wilkerson et al., 2010).  
KSHV associated PEL, too, have been classified into multiple subtypes on the 
basis of host gene expression (Gregory et al., 2009).   
We sought to identify if such groups exist in KS patients, and to determine 
if subpopulations correlate with any particular clinical feature such as HIV viral 
load in plasma, KSHV genome copy number in plasma, and immune status as 
ascertained by CD4 count.   
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METHODS: 
 Two hundred and seventeen KS patients at the UNC Lighthouse Clinic at 
Kamuzu Central Hospital in Lilongwe, Malawi were screened for enrollment into 
this study from November 2008 through August 2010.  Every patient seeking 
care at the clinic is evaluated for KS.  Patients who had been treated with ART or 
chemotherapy previously (105 patients, 48.4%) were excluded from the study.  
12 (5.5%) patients had KS limited to the oral cavity, and were rejected due to 
anticipated difficulty and patient risk in obtaining a biopsy from this region.  29 
patients (13.4%) were excluded for other reasons, not described.  The remaining 
70 patients (32.3%) were enrolled into this single- visit, observational study. 
Samples were missing from two patients, and were excluded, resulting in 68 
patients.  An additional 2 samples had failure of the internal control in the KSHV 
DNA assay, and were also excluded, since KSHV copies could not be 
determined accurately.  
Clinical data including age, gender, race, and health status for the 66 
patients were documented and are summarized in Table 3.1.  HIV viral load and 
CD4 count were determined.  KSHV viral load was assessed from plasma using 
an in-house assay (Tamburro and Dittmer, unpublished). 
 A 2mm KS biopsy was obtained from a representative lesion from study 
participants, and was stored in RNAlater™ (Ambion, Austin, TX) to prolong RNA 
integrity.  Samples were shipped to the University of North Carolina for 
processing.  Biopsies were stored at -80°C.  
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 Specimens were thawed on ice, biopsy was removed from RNAlater™ 
solution, and excess solution was removed with Kimwipe.  Biopsies were lysed 
with a BeadBeater using Trizol (Sigma-Aldrich, St Louis, MO).  RNA was 
quantified using a Nanodrop spectrophotometer.  Equal amounts of RNA were 
treated with Turbo-Free DNase (Life Technologies), and then reverse transcribed 
to generate cDNA using (High Capacity cDNA Reverse Transcriptase Kit, Life 
Technologies).   
A novel 192 primer pair array was designed to specifically amplify KSHV 
genes.  Redundant primers were included for each KSHV open reading frame 
(ORF), targeting both the 3’ and 5’ ends of each gene, where applicable.  
Reference genes for cellular transcripts were included for normalization.  Primers 
were designed using Primer3 (Rozen and Skaletsky, 2000) (Rozen and 
Skaletsky, 2000), and specificity was confirmed using BLAST. 
qPCR reactions were plated in 384 well plates using Tecan Freedom Evo 
liquid handling robot, and cycled and analyzed using Roche LightCycler 480, as 
previously described (Chugh, Tamburro, and Dittmer, 2010). 
A subpopulation of 26 of the 66 patients was randomly selected for the 
first group of gene expression analysis (Figure 3.1).  These samples comprised 
the training set, from which clusters were identified.  The remaining 40 samples 
were used as a test set to confirm subtypes discovered by the first group.  
Statistical analysis was performed using R v2.8.0 (Maindonald and Braun, 
2007) and Microsoft Excel.  
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RESULTS: 
All 66 patients were HIV-positive, with a median HIV plasma viral load of 
140,883 copies/ml (IQR- 58,025-291,603) (Table 3.1).  CD4 counts were 
generally low, with a median of 181 cells per cubic millimeter (IQR 79-261) of 
blood and with 57.6% having a count below 200 (38/66).  KSHV copies were 
determined from cell-fee plasma for all patients.  59 of the 66 patients (89.3%) 
had a KSHV plasma viral load above our lower limit of detection of 200cp/mL.  
The median copy number for these patients with detectable viral copies was 
1,448 cp/mL (IQR- 584- 5,435).  
To assess gene expression in KS tumor biopsies, we turned to high-
throughput qPCR arrays (Dittmer, 2003; Fakhari and Dittmer, 2002). 
Approximately 90 ORFs have been identified for KSHV (Ohsaki and Ueda, 2012) 
(Russo et al., 1996).  182 primer pairs were designed to amplify the entire 
transcriptome of KSHV, including redundant primers containing unique 
sequences for the same gene, to ensure coverage.  10 reference primer pairs (5 
genes- actin, hypoxanthine–guanine phosphoribosyltransferase (HPRT), glucose 
6-phosphate dehydrogenase (GAPDH), β2-microglobulin (β2M), and β –actin (β 
ACT); in duplicate) were also included on the array for normalization.  The 192 
primer pairs were prepared in two-96 well plates.  19 primer pairs were present 
on both plates to allow for normalization between plates.  
This design allowed us to conduct a detailed analysis of experimental 
errors. The between plate error for the same sample was calculated by 
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calculating the CT difference for each of 19 duplicate primers. It was 0.39 CT, 
with an IQR of 0.07 – 1.62 and CV of 1.59 (n= 27 samples). 
To confirm primer efficiency and to rule out unreliable primer pairs, the 
stringent statistical methods developed by Lock et al. (Lock et al., 2010) were 
used to purge  data of all nonlinear KSHV primers.  Briefly, DNA was extracted 
from KSHV virions, and a serial dilution of DNA was amplified with each primer 
pair in the array.  Primers demonstrating a nonlinear trend or poor r2 values (less 
than 0.9) were excluded from further analysis.  Of the 182 KSHV genes tested, 
153 primer pairs passed validation.  These primers spanned the entire genome 
(Figure 3.2A), and had a predicted average product size of approximately 190bp 
(Figure 3.2B). The specificity of the array was confirmed by analyzing the qPCR 
products on a sizing matrix (Caliper Inc.) (data not shown).  To validate the array, 
a dilution series of DNA isolated from KSHV positive BCBL1 cells was run.  As 
evident in Figure 3.2C, the array was accurately able to detect KSHV genes at 
decreasing levels with more dilute samples, and primer pairs were negative for 
water control, validating the assay.  Additionally, serial dilution analysis enabled 
the computation of CT’ values, as developed by Lock et al. (Lock et al., 2010).  
Rather than assuming a perfect qPCR efficiency of 2, i.e. doubling the amount of 
PCR products each cycle, this method uses actual, experimentally determined 
primer efficiency to calculate a modified CT value, which we call CT’.  Since 
many factors can effect PCR efficiency such as melting temperature, primer 
binding efficiency, and primer GC content, an ideal efficiency of 2 is not always 
achievable, and thus CT’ values are a more accurate figure.  
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To account for variation in sampling and reverse transcription, CT’ values 
were normalized to cellular cDNA levels (since trend analysis and r2 values were 
generated using encapsulated virus and not cellular DNA, reference genes were 
not be validated in this manner).  To assess the specificity of each primer, the 
melting temperatures (TM) were evaluated to ensure that only one peak was 
observed for each sample.  As primers were designed to amplify highly 
conserved regions of KSHV genes, the melting temperature for each primer pair 
should have very little or no variation between samples.  Notably, each primer 
demonstrated a very narrow range of TMs (data not shown).  Replicate primers 
on each primer plate had no difference in melting temperature, as expected 
(median SD of reference genes= 0.25).  Minor peaks for secondary melting 
temperatures were noticed for a few of the samples, and the CT’ values 
corresponding to these reactions were excluded from further analysis, as PCR 
contamination cannot be ruled out.  One replicate of the reference gene GAPDH 
failed for all samples, and was excluded from this and future analysis.  The 
remaining reference genes had a high correlation, indicating primer redundancy 
(Figure 3.3).  
To test the hypothesis that KS subgroups exist and display variation in 
gene expression, unsupervised classic correlation-based clustering by sample 
was performed (ArrayMiner). Before applying this statistical analysis we 
narrowed our training data set based on additional quality control steps.  First, 
the trimmed mean of raw CT values for reference genes (n = 9) and KSHV 
latency genes (n = 6) were plotted for each sample in order to detect limitation 
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cutoffs for our assay.  1 sample was excluded due to poor amplification (10% 
trimmed mean >30 cycles) of reference genes, indicating insufficient quantity or 
quality of cDNA (Figure 3.4a).  Expression of the latency transcript including 
LANA (Orf 73, primers 123511, replicates) and vFLIP (Orf72, primers 122381 
and 122443) was significantly lower (p=0.005, Wilcoxon Rank Test) for 10 
additional samples.  These samples were also excluded, as we expected that 
this likely reflects an expression level outside of our linear range or that few cells 
within the biopsy were KSHV positive. Two potential explanations exist- i) few 
tumor cells are present in the biopsy, or ii) the tumor cells present had low 
expression levels of latency genes.  These ten samples were excluded from the 
subpopulation. This resulted in n = 15 high quality data sets of comparable KSHV 
latency mRNA levels. 
CT’ values for validated KSHV primers were calculated using the 
transformed qPCR efficiencies as determined in the serial dilution experiment.  
CT’ values were then converted to dCT’ values by normalizing to the 10% 
trimmed mean of the confirmed reference genes.  To account for variation in the 
amount of KSHV positive tumor cells per biopsy, dCT’ values were then 
converted to ddCT’ values by normalization to the 10% trimmed mean of KSHV 
LANA and vFLIP genes.  We believe this second normalization process to be 
appropriate based on in situ mRNA hybridization, which show that all infected 
cells express latent mRNAs and a subset in addition also lytic mRNAs (Dittmer et 
al., 1998; Dupin et al., 1999; Staskus et al., 1997).  Hierarchical, unsupervised 
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clustering using Pearson correlation was used to determine if subpopulations of 
biopsies could be identified based on gene expression profiles.  
Two distinct clusters were identified using ArrayMiner by adopting the 
'classic clustering' method in the software.  'Classic clustering' computes class 
labels based on minimal variance criterion.  We visualize the 2 clusters in a 3 
dimensional space defined by first 3 principal component directions (Figure 3.4b 
and c).  
In one cluster, samples demonstrated evidence of genome-wide 
transcription of KSHV genes, including lytic genes (n=10).  The genes that were 
expressed highly in this cluster included K14, K4, K5, K7, Orf 56-62, although 
genome-wide low transcription was also noted. The second cluster (n=5) 
demonstrated exclusive expression of the latency transcript of KSHV, with little or 
no evidence of lytic mRNA transcription.  No individual genes were used to 
distinguish clusters- rather the overall pattern of gene expression was 
responsible for driving clustering groups.  Primers targeting the same gene and 
primer pair replicates clustered together, as expected (data not shown).   
While latency transcripts were expressed in all samples, expression of 
lytic genes was markedly increased only in tumors comprising the genome-wide 
transcription group. We next sought to identify specific mRNAs and specific 
primers that would constitute a minimal set or signature of genes that can 
differentiate between these two KS subtypes.  
Ad hoc inspection of the clustering results showed that the latent group 
demonstrated low levels of transcription, while the lytic cluster had high 
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expression of mRNAs for Orf50 (RTA, the lytic switch), Orf48 (immediate-early), 
Orf36 (Serine Protein Kinase (Park et al., 2000)), and RTA response elements 
(RRE) ORF29 and Orf52 (Coscoy, 2007).  As there is evidence for transcription 
of both early and late KSHV genes, this indicates that the lytic cycle, and 
therefore active viral replication is evident.   
To systematically identify mRNAs that were differentially expressed 
between the two clusters and thus could be developed into diagnostic 
biomarkers, chi square test (or Fisher Exact Test where appropriate) was used.  
Primers for lytic genes that had an unadjusted p value ≤0.1 were identified.  
These are shown in Table 3.2. 
To independently confirm that these lytic gene mRNAs vary between 
sample subpopulations, we tested the 40 remaining samples from the original 
cohort using only primers for these genes.  Following the analysis pipeline 
developed for the test data set, all samples were assessed for sufficient 
expression of human reference genes first (n = 9, primers= actin, GAPDH, and 
HPRT, in triplicate each), and then of the KSHV latency genes (n= 4, primers= 
ks76_122443, ks76_122381, ks77_123054, and ks77_123511).  7 samples were 
excluded due to poor expression of KSHV latency genes, following the logic as 
described for the previous subset (Figure 3.5a).  dCT’ was determined for the 
remaining 33 samples, and data was analyzed using unsupervised Pearson 
correlation clustering to determine if distinct clusters were again identifiable using 
only the gene signature primers,  i.e. analysis was limited to only the n = 20 
mRNAs (41 primers) that showed most significant gene expression differences 
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between the two groups from the training set.  Again, unsupervised clustering 
identified two subpopulations - those with (20/33) and those without (13/33) 
genome-wide transcription (Figure 3.5b and c).  The genes within the clusters 
were tightly correlated (scaled Jagota's Q = 0.0024) and two represents the 
optimal number of clusters (data not shown) 
To assess whether the two KS subtypes that we identified on the basis of 
intra-lesions KSHV mRNA levels were associated with distinct clinical and/or 
laboratory phenotypes we evaluated each subgroup with regard to log HIV 
copies, CD4 count, and log KSHV copies (Figure 3.6A-C).  The patients whose 
biopsies demonstrated KSHV genome-wide expression in one of their KS lesions 
did not have a significant difference in HIV or KSHV viral load compared to 
patients with low lytic gene expression (respectively, p= 0.845, p=0.284, T Test). 
However, patients in the lytic group had significantly higher CD4 counts 
(p=0.0487, T Test), with a mean of 162 CD4 cells per microliter (IQR 85-205) for 
the lytic and mean of 252 CD4 cells per microliter (IQR 101-365) for the tightly 
latent group.  Multivariate analysis was also used to determine the relationship of 
multiple factors with cluster.  As shown in Table 3.3, clusters did not differ 
significantly by combination of factors observed including HIV and KSHV viral 
load, CD4 count, age, BMI, pulse, Karnofsky Score or respiratory rate, i.e. the 
univariate trend towards higher CD4 counts associated with lytic KSHV 
transcription was not significant after correcting for other factors among the two 
groups. 
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Cluster classification was not different with regard to age, BMI, number of 
lesions, Karnofsky score, the presence of systemic illness, lymphadenophathy or 
B symptoms, or the presence of oral lesions by univariate or multivariate analysis 
(data not shown).  
 
DISCUSSION: 
KS is historically diagnosed by the visual detection of lesions, and KSHV 
viral load is seldom determined.  Here, we describe a method for the 
classification of KS tumors, based on the presence or absence of viral 
transcription within an indicator lesion.  A representative KS lesion was biopsied, 
RNA was extracted, and cDNA was synthesized and subjected to a KSHV whole 
genome array.  Patients were stratified into two clusters based on the expression 
of lytic genes, and clinical factors were assessed for differences. 
Previous work from our group has demonstrated that KS tumor subtypes 
exist, and that tumors can be stratified by their expression of lytic genes (Dittmer, 
2003; Dittmer, 2011; Krown, Dittmer, and Cesarman, 2011).   However, prior 
studies lacked detailed clinical data necessary to draw conclusions regarding the 
impact of these subtypes. They were confounded by different HAART exposure, 
by prior chemotherapy experience and restricted to AIDS KS in the US.  This 
study is novel in that it describes a population of KS that has not been studied 
before- newly diagnosed KS in HIV patients in Malawi, with matched clinical data.  
Importantly, our study describes therapy-naïve patients.  This is significant as we 
have shown that there are distinctions between transcription patterns between 
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samples collected pre-and post the era of HAART, which demonstrate an altered 
mode of KS pathogenesis upon HAART- controlled HIV (Dittmer, 2011).  The 
focus of this study is on KS in its natural host and prior to any intervention or 
treatment strategies to understand tumor microenvironment at time of KS 
diagnosis.   
Here, we demonstrate that subtypes as defined by intra-lesional profiling 
do not correlate with KSHV copies in the blood.  This evidence suggests that 
predominantly lytic and predominantly latent tumors result in a similar amount of 
virus in plasma. This suggests that, either one or a few lesions contribute the 
majority of circulating KSHV (a typical patients in our study had > 10 lesions of 
which we biopsied one at random), or that the circulating virus is derived from a 
reservoir/production site other than the KS skin lesions.  The lytic genes detected 
in the genome-wide transcription cluster were both early and late genes, which 
have roles in viral particle formation (i.e.- capsid proteins, RTA response 
elements, etc.).  We did not find lesions that expressed just vGPCR or just one 
particular lytic mRNA with a previously defined role in pathogenesis alone. This 
suggests that these lesions had a large number of cells in various stages of the 
lytic life cycle. Based on our prior experience with KSHV reactivation in culture, 
we surmise that differential detection and differential expression levels are the 
reason why not every mRNA was detectable in all “lytic” samples. Although it is 
unclear as to the role lytic gene expression in a single KS tumor may have in 
contributing to KSHV viremia, is it interesting to note that the tumor stage (T0 or 
T1) did not significantly vary between the lytic and latent subpopulations 
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(p=0.58).  Total lesion count also did not differ significantly between groups (p= 
0.165).  One possible explanation for the lack of correlation between KSHV 
viremia and lesion cluster may be that the tumor selected for biopsy may not be 
representative of all lesions.  
It is likely that the transcription pattern observed may also be reflective of 
tumor microenvironment.  For example, ORFs 34-37 are hypoxia induced (Haque 
et al., 2006), and tumors with increased expression of this transcript may 
represent a more hypoxic environment.  Additionally, many late mRNAs encoding 
for capsid and tegument proteins were detected, which represent expression of 
late genes.  It is important to note that while certain cDNAs were detected in 
many samples and while trends of expression were observed, tumors from 
different patients demonstrated unique expression profiles.  This reflects on the 
diversity of transcript profiles.  Future work is necessary to determine if the 
differences in specific genes expression patterns can be used to further classify 
tumor stage and type.  Another possibility is that this represents within-subject 
inter-lesion variation.   
An interesting trend was that in univariate analysis the CD4 count was 
higher in patients with lytic gene expression profiles. Although this may seem 
counterintuitive, this finding has been observed previously in Burkitt lymphoma 
(BL).  In a study by Guech-Ongey et al., BL was observed more commonly in 
patients with a CD4 count >250 when compared to patients with CD4 levels <50 
(Guech-Ongey et al., 2010).  A similar observation was also noted for KS 
patients (Casper et al., 2004).  While one might expect an opportunistic infection 
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such as KSHV or EBV to thrive under the most immunocompromised setting, one 
potential explanation for this finding is that tumorigenesis is dependent on the 
presence of functional CD4 cells, or that the signals emitted by even residual 
CD4 activity may result in viral reactivation.  
In summary, we identified distinct subpopulations of KS in therapy naïve 
AIDS patients, as characterized by viral gene expression profiling.  These 
subgroups are associated with CD4 count. No other clinical characteristic differed 
between clusters.  This represents an important new classification of tumors, 
which may have important implications on response to therapeutics.  Future 
studies will be needed to understand how the subpopulations observed here 
differ in prognosis and response to therapy.   
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TABLES AND FIGURES 
 
 
TABLE 3.1: Cohort Demographics for 66 therapy-naïve KS HIV+ 
patients in Lilongwe, Malawi 
  
  
Gender 
 Male 47 71% 
 Female 19 29% 
  
Race 
 Black African, non-Hispanic 66 100% 
  
Age 
 19- 29 20 30% 
 30- 40 37 56% 
 41- 51 9 14% 
  
CD4 count 
 >200 38 58% 
 <200 28 42% 
  
K score 
 <70 11 17% 
 >70 55 83% 
  
Tumor edema 
 yes 30 45% 
 no 36  55% 
  
Weight loss  
 yes 37 56% 
 no 29 44% 
  
KSHV cp/ml 
 Average 5,336 
 (range) (<200-59,455) 
  
HIV cp/ml 
 Average 198,592 
 (range) (2,663-750,000) 
  
CD4 count 
 Average 203 
 (range) (7-772)
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FIGURE 3.1: Sample and Data Analysis Work Flow Chart 
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From the original 71 samples, 66 were used for analysis.  Samples were 
subdivided into a training set, which was used to develop the assay, and a test 
set.  The training set was devised to determine if subpopulations of samples 
could be distinguished using gene expression arrays, and to determine which 
genes were critical for determining group classification. Only these primers were 
used to determine subpopulations for the test set.  Members of the lytic group or 
the latent group from each experiment were combined to determine similarities 
between clinical characteristics in each subpopulation.   
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FIGURE 3.2: KSHV Array Characteristics and its Validation 
 
 
 
 
 
A novel KSHV qPCR array was designed to contain 182 primer pairs directed 
towards KSHV genes, and another 10 primer pairs for amplification of 
housekeeping reference genes.  The KSHV primer pairs were positioned 
spanning the entire viral genome (A) and all PCR products were designed to 
have a similar size of approximately 200bp (B), enabling the ability to perform all 
reactions under a single set of conditions.  To confirm the array, BCBL1 DNA 
was diluted 1:4 serially (C) and run on the array.  A negative control water was 
included for validation.  Black indicates no amplification, while lighter bands 
reflect a lower CT value, indicating greater amplification.   
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FIGURE 3.3: Correlation of Reference Genes 
 
BACT1
actin2
actin1
BACT2
GAPDH2
B2M2
B2M1
HPRT2
HPRT1
Figure 2- Correlation of Reference Genes
 
Reference genes were highly correlated with one another. The filled-in portions 
of the circles indicate the percentage correlation between the two primers. The 
correlation plot on the bottom indicated the percent correlation based on 
deepness of color, while the lines indicate a positive correlation. 
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FIGURE 3.4: Gene Expression Profiling of Training Subset of Samples 
Indicate Two Distinct Clusters of Samples Exist 
 
 
 
 
 
(A) For each sample, the 10% trimmed mean for reference gene primers were 
plotted against the trimmed mean for KSHV latency genes.  The limit of detection 
was determined to be 40 CT for latency genes and 30 CT for reference genes.  
Only samples in the bottom left quadrant were used in subsequent gene 
expression analysis (n=15). (B) Using ddCT values, a heatmap was generated 
using Principle Component Analysis (PCA) and Pearson based clustering.  Two 
distinct clusters of gene expression profiles were evident for the remaining 15 
samples.  On the top, samples with genome-wide transcription are evident 
(termed “lytic” cluster).  The bottom cluster represents the latent cluster, where 
expression is lower.  Light color indicates greater expression. (C) Cluster 
assignment is distinct and robust, as demonstrated by PCA plot. 
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TABLE 3.2: Significant Primers (p<.1) were Identified from Training 
Data Set 
 
 
Primer P Value 
K4 (21778)   0.042 
K4 (21778)   0.084 
Orf 11 or 10,9,8,7,6,4 (16677) 0.077 
Orf 34 or Orf35 (55680)   0.042 
ORF17 or Orf17.5 (31509)  0.042 
Orf32 or 29,30,31 (52828) 0.084 
Orf37 or 34,35,36 (57765,2)   0.002 
Orf37 or 34,35,36 (57765) 0.042 
Orf37 or 34,35,36 (58237) 0.002 
Orf46,47,48 (69318)       0.084 
Orf49 or 50 (71851)       0.047 
Orf56 or 57 (83216)       0.000 
Orf58 or 59,60,61,62 (94692)  0.000 
Orf58 or 59,60,61,62 (94950)  0.004 
Orf58 or 59,60,61,62 (95417)  0.004 
Orf59,60,61,62 (95961)    0.022 
Orf59,60,61,62 (96407)    0.017 
Orf61 or 62 (98333)       0.084 
Orf66 or 67, 67A (112774) 0.002 
Orf66 or 67, 67A (114218) 0.084 
 
 
Chi square test or Fisher Test (where appropriate) was used to determine 
individual primers that had a p value <0.1.  P value was not adjusted for multiple 
comparisons. 
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FIGURE 3.5: Gene Expression Analysis of 33 Additional Samples 
Confirm Two Clusters of Biopsies Are Distinguishable 
 
 
 
 
 
(A) The 10% trimmed mean for reference and latency genes were determined for 
the remaining 40 samples, and cutoff limits were determined.  Samples with a 
value >38 for Latency genes were excluded.  (B) The remaining 33 samples 
were analyzed for gene expression profiles by PCA using Pearson correlation, 
using only primers that were significantly different between clusters from the 
training set.  (C) Two distinct clusters were apparent using PCA. 
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FIGURE 3.6: There Are Significant Differences in CD4 Count Between 
Two Groups, But No Difference in HIV or KSHV Viremia 
 
 
 
 
Clinical data from both experiments were pooled based on cluster profile, and T 
test was used to determine significant differences between groups.  (A) HIV viral 
load was not significantly different between groups (p=.84), although (B) CD4 
was significantly increased in biopsies in the lytic cluster by t test (.0487).  (C) 
KSHV viremia was also indistinguishable between clusters (p=.2837). 
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TABLE 3.3: Multivariate Analysis Reveals that No Statistically 
Significant Factors Can be used to Distinguish Observed Clusters 
 
Factors Estimate std. error P value Confidence Interval 
    Lower bound Upper bound 
Intercept 5.0346 4.95446 0.31 -4.675963239 14.74516324 
Age -0.05268 0.05563 0.344 -0.161712797 0.056352797 
BMI -0.06008 0.10512 0.568 -0.266111416 0.145951416 
Pulse 0.00661 0.01857 0.722 -0.029786531 0.043006531 
Resp 0.01367 0.07397 0.853 -0.131308537 0.158648537 
CD4 0.09506 0.06952 0.172 -0.041196697 0.231316697 
HIV -0.31688 0.32692 0.332 -0.957631431 0.323871431 
KSHV 0.06284 0.25461 0.805 -0.436186434 0.561866434 
Karnofsky 
Score >70 
-0.22353 0.93747 0.812 -2.060937451 1.613877451 
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APPENDIX 3.1: PEA.R- Code to Calculate CT’ Values 
 
IdentifyUnreliable = function(Data, Dilution, Display = FALSE){ 
 
X <- log2(Dilution); 
Width <- length(Data) 
Length <- length(Data[,1]) 
 
Slope <- c() 
LowerBnd <- c() 
UpperBnd <- c() 
Yintercept <- c() 
Rsquare <- c() 
for(i in 1:Length){ 
 Slope[i] <- lm(t(Data[i,3:Width]) ~ X)$coefficients[2] 
 LowerBnd[i]<-confint(lm(t(Data[i,3:Width])~X),"X", 0.90)[1] 
 UpperBnd[i]<-confint(lm(t(Data[i,3:Width])~X),"X", 0.90)[2] 
 Rsquare[i] <- summary(lm(t(Data[i,3:Width]) ~ X))$r.squared   
} 
Insignificant <- Data$primer[UpperBnd>0] 
 
PurgedData<-subset(Data, UpperBnd<0); 
Slope <- subset(Slope, UpperBnd < 0); 
LowerBnd <- subset(LowerBnd, UpperBnd < 0); 
Rsquare <- subset(Rsquare, UpperBnd < 0); 
UpperBnd <- subset(UpperBnd, UpperBnd < 0); 
 
Keff <- 2^(-1/Slope); 
LowerKeff <- 2^(-1/LowerBnd); 
UpperKeff <- 2^(-1/UpperBnd); 
 
KeffLength <- UpperKeff-LowerKeff 
Unreliable <- PurgedData$primer[KeffLength > quantile(KeffLength, .75)+1.5*IQR(KeffLength)] 
PurgedData <- subset(PurgedData, KeffLength < quantile(KeffLength, .75)+1.5*IQR(KeffLength)) 
 
if(Display == TRUE){ 
 plot(Keff[KeffLength < 3], KeffLength[KeffLength < 3], xlab = "Efficiency", ylab = "Length of 
Transformed CI", main = "Efficiency Vs Transformed CI", pch = 19, cex = 1.7) 
 points(Keff[KeffLength > quantile(KeffLength, .75)+1.5*IQR(KeffLength)], KeffLength[KeffLength 
> quantile(KeffLength, .75)+1.5*IQR(KeffLength)], pch = 19, col = 'red', cex = 1.7)  
} 
return(list(Purged = PurgedData, Insignificant = Insignificant, Unreliable = Unreliable)) 
} 
############################################## 
ClusterEffs <- function(PurgedData, Dilution, Display = FALSE){ 
#PurgedData = NewData$Purged 
#Dilution = c(1,.2,.04,.008,.0016,.00032) 
#Display = TRUE 
 
Length <- length(PurgedData[,1]) 
Width <- length(PurgedData[1,]) 
X <- log2(Dilution) 
 
Keff <- c() 
for(i in 1:Length){ 
 90 
 Slope <- lm(PurgedData[i,3:Width] ~ X)$coefficients[2] 
 Keff[i] <- 2^(-1/Slope) 
} 
PurgedData.Sorted <- PurgedData[order(Keff),] 
Y <- c() 
for(i in 3:Width){ 
    Y <- c(Y, PurgedData.Sorted[,i])} 
newX <- rep(X, each = Length) 
#Primer <- rep(PurgedData.Sorted$primer, length(Dilution)) 
Primer <- rep(PurgedData.Sorted[,2], length(Dilution)) 
 
Groups <- matrix(nrow=Length, ncol=Length) 
BestRsquare <- 0 
Groups[,1] <- sample(1,Length, TRUE) 
for(k in 2:Length){ 
 for(i in 1:(k-1)){   
   for(j in 1:(sum(Groups[,k-1]==i)-1)){ 
 Dummy <- Groups[,k-1] 
 Dummy[Groups[,k-1]==i] <- c(rep(i,j), rep(k,sum(Groups[,k-1]==i)-j)) 
 Rsquare <- summary(lm(Y ~ newX:factor(rep(Dummy,length(Dilution))) + 
factor(Primer)))$r.squared 
 if(Rsquare>BestRsquare){ 
  BestRsquare <- Rsquare 
  Groups[,k]<-Dummy 
      } 
  }} 
 if(k==2) 
    p <- anova(lm(Y ~ newX+ factor(Primer)), lm(Y ~ newX:factor(rep(Groups[,k],length(Dilution))) 
+ factor(Primer)))$Pr[2] 
 else 
    p <- anova(lm(Y ~ newX:factor(rep(Groups[,k-1],length(Dilution))) + factor(Primer)), lm(Y ~ 
newX:factor(rep(Groups[,k],length(Dilution))) + factor(Primer)))$Pr[2] 
 if((p > 0.05)){ 
    Group <- Groups[,k-1]  
    NumClusts <- k-1 
    break;  
 }} 
 
cat("Found ") 
cat(NumClusts) 
cat(" clusters. \n") 
 
if(Display == TRUE){ 
  ClusColors <- rep(c("red", "green", "blue", "yellow", "black", "purple", "brown", colors()[79], 
colors()[450], colors()[81], colors()[209]), 1+NumClusts/12) 
  stripchart(sort(Keff), col = "white", xlab = "Efficiency", main = "Primer Efficiency Clusters") 
  title(main = "Primer Efficiency Clusters") 
  for(i in 1:NumClusts) 
   stripchart(sort(Keff)[Group==i], method = "jitter", jitter=.1, add=TRUE, col = ClusColors[i], 
pch=".", cex = 9) 
} 
Group_Unsorted <- Group[rank(Keff)] 
Efficiencies <- c() 
for(i in 1:NumClusts){ 
 Efficiencies[Group_Unsorted==i] <- mean(sort(Keff)[Group==i]) 
} 
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 return(Efficiencies) 
} 
 
############################################################# 
AdjustCt <- function(Data, Efficiencies){ 
 Width <- length(Data) 
 Adjusted <- Data 
 Adjusted[, 3:Width] <- log2(Efficiencies^Data[,3:Width])  
 return(Adjusted) 
} 
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APPENDIX 3.2: R Code Using PEA.R to Calculate CT’ 
 
# this code is to calculate CT' based on CT values 
# Efficiencies are calculated from training set with the same set of primers 
# Notice that for different primers in training set,  
# the number of CT value measured are different 
 
library(xlsx) 
data=read.xlsx('CT_training_PP1.xlsx',sheetIndex=1) 
data 
length=dim(data)[1] 
#width=dim(data)[2] #==7 
CT5=matrix(nrow=length,ncol=7) # subset with 5 CTs measured 
CT6=matrix(nrow=length,ncol=8) # subset with 6 CTs measured 
CT7=matrix(nrow=length,ncol=9) # subset with 7 CTs measured 
i5=1 
i6=1 
i7=1 
ind5=rep(0,length) 
ind6=rep(0,length) 
ind7=rep(0,length) 
for(i in 1:length){ 
 n=sum(is.na(data[i,])) 
 if(n==2){ 
  CT5[i5,]=as.matrix(data[i,1:7]) 
  ind5[i5]=i 
  i5=i5+1 
  } 
 if(n==1){ 
  CT6[i6,]=as.matrix(data[i,1:8]) 
  ind6[i6]=i 
  i6=i6+1 
  } 
 if(n==0){ 
  CT7[i7,]=as.matrix(data[i,1:9]) 
  ind7[i7]=i 
  i7=i7+1 
  } 
 } 
CT5=na.omit(CT5) 
CT6=na.omit(CT6) 
CT7=na.omit(CT7) 
ind5=ind5[ind5!=0] 
ind6=ind6[ind6!=0] 
ind7=ind7[ind7!=0] 
 
# use Lock's code to calculate beta1/efficienct related to each primer 
setwd('/Users/Tam/Desktop') 
source('PEA3.r') 
eff5=ClusterEffs(CT5, c(16,64,256,1024,4096), Display = T) 
eff6=ClusterEffs(CT6, c(4,16,64,256,1024,4096), Display = T) 
eff7=ClusterEffs(CT7, c(1,4,16,64,256,1024,4096), Display = T) 
 
# combine estimated efficiencies together in original order 
ind=c(ind5,ind6,ind7) 
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primer=c(CT5[,2],CT6[,2],CT7[,2]) 
eff=c(eff5,eff6,eff7) 
eff.matrix=cbind(primer,eff) 
eff.sorted=eff.matrix[order(ind),] 
eff.sorted 
 
 
# calculate new CT' 
new.data=read.csv("toR_calcCT'_no60.csv") 
index=(new.data[,8]=='good') & ((new.data[,9]=='PP1')) 
new.data=new.data[index,] 
dim(new.data) 
CT=new.data[,10:25] 
scale=c(log2(as.numeric(eff.sorted[,2]))) 
CT.prime=CT*scale 
new.sheet=cbind(eff.sorted[,1],CT.prime) 
write.xlsx(new.sheet,file='121412_OUTPUT-CT prime_PP1_no60.xlsx') 
 
 
#-------------------------------------------------------------------------------------- 
data=read.xlsx('CT_training_PP2.xlsx',sheetIndex=1) 
data 
length=dim(data)[1] 
#width=dim(data)[2] #==7 
CT5=matrix(nrow=length,ncol=7) # subset with 5 CTs measured 
CT6=matrix(nrow=length,ncol=8) # subset with 6 CTs measured 
CT7=matrix(nrow=length,ncol=9) # subset with 7 CTs measured 
i5=1 
i6=1 
i7=1 
ind5=rep(0,length) 
ind6=rep(0,length) 
ind7=rep(0,length) 
for(i in 1:length){ 
 n=sum(is.na(data[i,])) 
 if(n==2){ 
  CT5[i5,]=as.matrix(data[i,1:7]) 
  ind5[i5]=i 
  i5=i5+1 
  } 
 if(n==1){ 
  CT6[i6,]=as.matrix(data[i,1:8]) 
  ind6[i6]=i 
  i6=i6+1 
  } 
 if(n==0){ 
  CT7[i7,]=as.matrix(data[i,1:9]) 
  ind7[i7]=i 
  i7=i7+1 
  } 
 } 
CT5=na.omit(CT5) 
CT6=na.omit(CT6) 
CT7=na.omit(CT7) 
ind5=ind5[ind5!=0] 
ind6=ind6[ind6!=0] 
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ind7=ind7[ind7!=0] 
 
# use Lock's code to calculate beta1/efficienct related to each primer 
setwd('/Users/Tam/Desktop') 
source('PEA3.r') 
eff5=ClusterEffs(CT5, c(4096, 1024, 256, 64, 16), Display = T) 
eff6=ClusterEffs(CT6, c(4096, 1024, 256, 64, 16, 4), Display = T) 
eff7=ClusterEffs(CT7, c(4096, 1024, 256, 64, 16, 4, 1), Display = T) 
 
# combine estimated efficiencies together in original order 
ind=c(ind5,ind6,ind7) 
primer=c(CT5[,2],CT6[,2],CT7[,2]) 
eff=c(eff5,eff6,eff7) 
eff.matrix=cbind(primer,eff) 
eff.sorted=eff.matrix[order(ind),] 
eff.sorted 
 
 
# calculate new CT' 
new.data=read.csv("toR_calcCT'_no60.csv") 
index=(new.data[,8]=='good') & ((new.data[,9]=='PP2')) 
new.data=new.data[index,] 
dim(new.data) 
CT=new.data[,10:25] 
scale=c(log2(as.numeric(eff.sorted[,2]))) 
CT.prime=CT*scale 
new.sheet=cbind(eff.sorted[,1],CT.prime) 
write.xlsx(new.sheet,file='121412_OUTPUT-CT prime_PP2_no60.xlsx') 
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APPENDIX 3.3: R Code to Determine Correlation Between Cluster 
Assignment and Clinical Characteristics 
 
library(gdata) 
library(MASS) 
library(DAAG) 
library(RColorBrewer) 
library(FactoMineR) 
library(heatmap.plus) 
library(ggplot2) 
library(DMwR) 
 
 
cohort <- read.csv("010713_forboxplot.csv", header=TRUE) 
drop.levels(cohort) 
summary(cohort) 
names(cohort) 
head(cohort) 
 
 
neg <- subset(cohort, cohort$Group==0) 
pos <- subset(cohort, cohort$Group==1) 
 
 
par(mfrow=c(3,2)) 
 
t.test(neg$hivpbmc,pos$hivpbmc) 
wilcox.test(neg$hivpbmc,pos$hivpbmc) 
boxplot(neg$hivpbmc,pos$hivpbmc, names=c("latent","lytic"), ylab= "cp/mL", col=c("grey22", 
"white"), main= "HIV PBMC") 
 
t.test(log(neg$hivpbmc),log(pos$hivpbmc)) 
wilcox.test(log(neg$hivpbmc),log(pos$hivpbmc)) 
boxplot(log(neg$hivpbmc), log(pos$hivpbmc), names=c("latent","lytic"), ylab= "log(cp/mL)", 
col=c("grey22", "white"), main= "LOG HIV PBMC") 
 
 
t.test(neg$cd4count, pos$cd4count) 
wilcox.test(neg$cd4count, pos$cd4count) 
boxplot(neg$cd4count,pos$cd4count, names=c("latent","lytic"), ylab= "cells/mm^3", 
col=c("grey22", "white"), main= "CD4 Count") 
 
 
#t.test(sqrt(neg$cd4count), sqrt(pos$cd4count)) 
#wilcox.test(sqrt(neg$cd4count), sqrt(pos$cd4count)) 
#boxplot(sqrt(neg$cd4count),sqrt(pos$cd4count), names=c("latent","lytic"), ylab= "square root 
(cells/mm^3)", col=c("grey22", "white"), main= "Square Root CD4 Count") 
 
t.test((neg$cd4count)^1/3, (pos$cd4count)^1/3) 
wilcox.test((neg$cd4count)^1/3, (pos$cd4count)^1/3) 
boxplot((neg$cd4count)^1/3, (pos$cd4count)^1/3, names=c("latent","lytic"), ylab= "cube 
root(cells/mm^3)", col=c("grey22", "white"), main= "Cube Root CD4 Count") 
 
 
t.test(neg$cpsKSHV, pos$cpsKSHV) 
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wilcox.test(neg$cpsKSHV, pos$cpsKSHV) 
boxplot(neg$cpsKSHV, pos$cpsKSHV, names=c("latent","lytic"), ylab= "cp/mL", col=c("grey22", 
"white"), main= "Copies KSHV") 
 
t.test(log(neg$cpsKSHV), log(pos$cpsKSHV)) 
wilcox.test(log(neg$cpsKSHV), log(pos$cpsKSHV)) 
boxplot(log(neg$cpsKSHV), log(pos$cpsKSHV), names=c("latent","lytic"), ylab= "cp/mL", 
col=c("grey22", "white"), main= "Log Copies KSHV") 
 
t.test(neg$cd4under200, pos$cd4under200) 
wilcox.test(neg$cd4under200, pos$cd4under200) 
boxplot(log(neg$cd4under200), log(pos$cd4under200), names=c("latent","lytic"), ylab= "CD4 
under 200?", col=c("grey22", "white"), main= "CD4 Under 200") 
 
 
t.test(neg$age, pos$age) 
wilcox.test(neg$age, pos$age) 
 
t.test(neg$resultscoret, pos$resultscoret) 
wilcox.test(neg$resultscoret, pos$resultscoret) 
 
t.test(neg$tumor0, pos$tumor0) 
wilcox.test(neg$tumor0, pos$tumor0) 
 
t.test(neg$tumor1edema, pos$tumor1edema) 
wilcox.test(neg$tumor1edema, pos$tumor1edema) 
 
t.test(neg$gender, pos$gender) 
wilcox.test(neg$gender, pos$gender) 
 
t.test(neg$weightloss, pos$weightloss) 
wilcox.test(neg$weightloss, pos$weightloss) 
 
t.test(neg$weightkg, pos$weightkg) 
wilcox.test(neg$weightkg, pos$weightkg) 
 
t.test(neg$heightcm, pos$heightcm) 
wilcox.test(neg$heightcm, pos$heightcm) 
 
t.test(neg$temperature, pos$temperature) 
wilcox.test(neg$temperature, pos$temperature) 
 
t.test(neg$pulsebpm, pos$pulsebpm) 
wilcox.test(neg$pulsebpm, pos$pulsebpm) 
 
t.test(neg$resp, pos$resp) 
wilcox.test(neg$resp, pos$resp) 
 
t.test(neg$skinlesion1, pos$skinlesion1) 
wilcox.test(neg$skinlesion1, pos$skinlesion1) 
 
t.test(neg$skinlesion2, pos$skinlesion2) 
wilcox.test(neg$skinlesion2, pos$skinlesion2) 
 
t.test(neg$skinlesion3, pos$skinlesion3) 
wilcox.test(neg$skinlesion3, pos$skinlesion3) 
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t.test(neg$skinlesion4, pos$skinlesion4) 
wilcox.test(neg$skinlesion4, pos$skinlesion4) 
 
t.test(neg$skinlesion5, pos$skinlesion5) 
wilcox.test(neg$skinlesion5, pos$skinlesion5) 
 
t.test(neg$lymphnode, pos$lymphnode) 
wilcox.test(neg$lymphnode, pos$lymphnode) 
 
t.test(neg$tumor1oral, pos$tumor1oral) 
wilcox.test(neg$tumor1oral, pos$tumor1oral) 
 
t.test(neg$tumor1viscera, pos$tumor1viscera) 
wilcox.test(neg$tumor1viscera, pos$tumor1viscera) 
 
t.test(neg$systemillness0, pos$systemillness0) 
wilcox.test(neg$systemillness0, pos$systemillness0) 
 
t.test(neg$systemillness0nohistory, pos$systemillness0nohistory) 
wilcox.test(neg$systemillness0nohistory, pos$systemillness0nohistory) 
 
names(cohort) 
 
t.test(neg$systemillness0status10, pos$systemillness0status10) 
wilcox.test(neg$systemillness0status10, pos$systemillness0status10) 
 
t.test(neg$systemillness1thrush, pos$systemillness1thrush) 
wilcox.test(neg$systemillness1thrush, pos$systemillness1thrush) 
 
t.test(neg$systemillness1bsymptoms, pos$systemillness1bsymptoms) 
wilcox.test(neg$systemillness1bsymptoms, pos$systemillness1bsymptoms) 
 
t.test(neg$systemillness170, pos$systemillness170) 
wilcox.test(neg$systemillness170, pos$systemillness170) 
 
t.test(neg$resultscores, pos$resultscores) 
wilcox.test(neg$resultscores, pos$resultscores) 
 
t.test(neg$cd4count, pos$cd4count) 
wilcox.test(neg$cd4count, pos$cd4count) 
 
t.test(neg$hivpbmc, pos$hivpbmc) 
wilcox.test(neg$hivpbmc, pos$hivpbmc) 
 
names(cohort) 
 
t.test(neg$VIRACORE.cps.KSHV, pos$VIRACORE.cps.KSHV) 
wilcox.test(neg$VIRACORE.cps.KSHV, pos$VIRACORE.cps.KSHV) 
 
t.test(neg$X_merge, pos$X_merge) 
wilcox.test(neg$X_merge, pos$X_merge) 
 
t.test(neg$genT1, pos$genT1) 
wilcox.test(neg$genT1, pos$genT1) 
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t.test(neg$Kover70, pos$Kover70) 
wilcox.test(neg$Kover70, pos$Kover70) 
 
t.test(neg$cd4under200, pos$cd4under200) 
wilcox.test(neg$cd4under200, pos$cd4under200) 
 
t.test(neg$bmi, pos$bmi) 
wilcox.test(neg$bmi, pos$bmi) 
 
t.test(neg$bmi_low, pos$bmi_low) 
wilcox.test(neg$bmi_low, pos$bmi_low) 
 
t.test(neg$numberoflessions, pos$numberoflessions) 
wilcox.test(neg$numberoflessions, pos$numberoflessions) 
 
t.test(neg$age_cat, pos$age_cat) 
wilcox.test(neg$age_cat, pos$age_cat) 
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APPENDIX 3.4: R Code- Calculate Primers That Vary Significantly 
Between Clusters 
 
####################################################################### 
# INTRODUCTION: 
# the entry of this code is a matrix, each entry is a delta CT (dCT) value 
# each column is consist of dCT values different types of genes (lytic or latent) 
# we will loop through columns and proceed as follows: 
# do a 2-mean clustering in each column and assign dCTs to two groups: high and low 
# we all know that which dCT come from which types of genes (lytic ot latent), so that a Chi-sq 
test 
# or a fisher's exact test will applied to a contingency table in the format 
#                           ------------------------------------------- 
#                           |            |  high group   | low group    
#                           |------------|----------------------------- 
#                           |  Latent    |      n11      |     n21      
#                           |------------|---------------|------------- 
#                           |  Lytic     |      n12      |     n22      
#                           |------------|---------------|------------- 
# 
# the choice of Chi-sq or fisher's exact test are based on the entries of above table, if  
# all n11,n12,n21,n22 are bigger than 5, we adopt Chi-sq, otherwise exact test. 
# The null hyothesis test for exact test is H0: Prob(high group|latent)=Prob(high group|lytic) 
# The null hyothesis test for Chi-sq test is H0: being high or low does not depend on gen type 
 
# notice that, latent and lytic as tags are prespecified by the users 
# 
# Jie Xiong 
# Dittmer Lab, UNC Chapel-Hill 
# Version:2012-08−28 
####################################################################### 
 
library(gdata) 
 
# read in the matrix first 
getwd() 
setwd('/Users/Tam/Desktop') 
# put your own directory here 
data<- read.csv('121812_CalcSigPrimers.csv') 
gene<-data[,1] 
data<-data[,2:dim(data)[2]] 
sample<-colnames(data) 
 
# transpose the data 
data<-t(data) 
# pre-processing data to make it clean 
row.num<-dim(data)[1] 
col.num<-dim(data)[2] 
 
 
# if there are any missing value, replace with column mean (which can be modifide) 
if(any(is.na(data))){ 
 # loop through columns to replace the missing value 
 for (i in 1:dim(data)[2]){ 
  if(any(is.na(data[,i]))) data[is.na(data[,i]),i] <- mean(data[,i], na.rm = TRUE) 
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 }  
} 
 
 
# let lytic_latent be a prespecified vector to classify genes 
# in terms of 1's and 2's, 1 represent lytic, 2 represents latent 
# the following are the toy example  
lytic_latent=cbind(t(rep(1,10)),t(rep(2,5)))  # the indicators are crucial 
 
data 
# loop through the columns  
# 2-mean clustering and conduct proper test 
P<- c(1:dim(data)[2]) # initialize P-values 
for (i in 1:dim(data)[2]){ 
 d<-data[,i] # this is current vector to be clustered using 2-mean 
 if(var(d)==0){ 
  P[i]=1 
 } 
 if(var(d)!=0){ 
 two.mean<-kmeans(d,2,iter.max=100,nstart=1,algorithm='Hartigan-Wong') 
    cluster.index<-two.mean$cluster 
    # assign two clusters to high and low  
    if (mean(d[cluster.index==1])>mean(d[cluster.index==2])) { 
     high<-abs(cluster.index-2) 
     low<-cluster.index-1 
     } 
    if (mean(d[cluster.index==1])<mean(d[cluster.index==2])) { 
     high<-cluster.index-1 
     low<- abs(cluster.index-2) 
     } 
     # high and low: index of two groups 
     dh=d[high==1] 
     dl=d[low==1] 
     # preparation for the test, to specify n11, n12, n21, n22 
     #              -------------------------------------------- 
  #              |            |  high group   | low group   | 
  #              |------------|-----------------------------| 
  #              |  Latent    |      n11      |     n21     |     
  #              |------------|---------------|-------------| 
  #              |  Lytic     |      n12      |     n22     |     
  #              |------------|---------------|-------------| 
  # 1 represent lytic, 2 represents latent 
  n11=length(d[(lytic_latent==2)&high]) 
  n21=length(d[(lytic_latent==2)&low]) 
  n12=length(d[(lytic_latent==1)&high]) 
  n22=length(d[(lytic_latent==1)&low]) 
   
  # start the test 
  entry<-matrix(c(n11,n21,n12,n22),nr=2,dimnames=list(c('latent','lytic'),c('high','low'))) 
  if(min(n11,n12,n21,n22)>5){ 
   stat<-chisq.test(entry) # no continuity correction applied here 
   s=stat$statistic 
   dof<-stat$parameter 
   P[i]<-pchisq(s,dof,lower.tail=F) # reject the upper tail  
  } 
  if(min(n11,n12,n21,n22)<=5){ 
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   stat<-fisher.test(entry,alternative='greater') # this is a one-sided test 
   P[i]=stat$p.value 
  } 
  } 
} 
P # this is the column-wise P-value 
P<-matrix(P,dimnames=list(names(data))) 
# then filter out the columns with significant P-value (cut-off is 0.05) 
# you can change the significance level to 0.1 if necessary,and the output will show you the P-
value for siginificant genes too 
alpha<-0.1 
sig.P<-matrix(P[P<alpha],dimnames=list(gene[P<alpha],c('P_value'))) 
alpha 
sig.P 
   
      
     
 
 
CHAPTER IV. 
VIRONOME OF KAPOSI SARCOMA-ASSOCIATED 
HERPESVIRUS-INFLAMMATORY CYTOKINE SYNDROME IN AN 
AIDS PATIENT REVEALS CO-INFECTION OF HUMAN 
HERPESVIRUS 8 AND HUMAN HERPESVIRUS 6A 
 
 
PREFACE 
 This work was previously published in Virology in November 2012 3.  This 
project began as a search for an infectious cause of the rapid decline in an AIDS 
patient in 2009.  My role in this project included researching and drafting the 
manuscript, performing the experiments, and assisting with analysis.  Dongmei 
Yang analyzed sequencing results (Figure 4.2).  Charles van der Horst, Jessica 
Poisson, Yuri Fedoriw, Amy Lucas, Nadia Malouf, Vincent Moylan, and Stephan 
Moll were the clinicians responsible for the patient’s care as well as autopsy 
findings.  Debasmita Roy and Sang Hoon Sin performed the initial PCR for KSHV 
(Figure 5.1E).  Dirk Dittmer was the principle investigator of the study and 
designed the experiments, analyzed the data and wrote the manuscript. 
 
_______________________________________ 
3 Tamburro, K.M., Yang, D., Poisson, J., Fedoriw, Y., Roy, D., Lucas, A., Sin, S.H., 
Malouf, N., Moylan, V., Damania, B., Moll, S., Van der Horst, C., Dittmer, D.P. 
Vironome of Kaposi Sarcoma-associated herpesvirus-inflammatory cytokine 
syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human 
herpesvirus 6A, Virology, 2012
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INTRODUCTION 
Kaposi Sarcoma (KS) and the plasmablastic variant of multicentric 
Castleman disease (MCD) are associated with Kaposi Sarcoma associated 
herpesvirus (KSHV) infection and occur with increased prevalence in AIDS 
patients. KS remains among the leading causes of death for people living with 
HIV/AIDS today. It is the most frequent cancer overall in many Sub Saharan 
countries (e.g. Uganda) (Franceschi et al., 2008).  Since skin KS lesions are 
relatively easy to diagnose clinically, KSHV viral load assays are seldom 
conducted. KSHV gene transcription in KS is variable, but predominantly 
restricted to the latent viral genes (Dittmer, 2003, Dittmer, 2011). Compared to 
diseases cause by other herpesviruses (HSV-1, CMV, EBV) systemic viremia in 
KS is an order of magnitude less (Lin et al., 2009).  As a consequence, infectious 
virus has not been efficiently recovered from patients, perhaps due to 
comparatively low systemic viremia vis-à-vis other herpesviruses. There exists a 
gap in our knowledge as all known sequence information for KSHV was derived 
from cell line propagated or tumor derived clones, but not free virus systemically 
replicating in the natural host. 
MCD is a hyperproliferative B cell disorder. MCD patients express high 
levels of viral IL6 (vIL6) and human IL6, which are thought to be responsible for 
the systemic illness and inflammatory symptoms (Brandt et al., 1990, 
Oksenhendler et al., 2000).  Clinical symptoms of MCD include edema, weight 
loss, pleural effusion (mostly cell free, as opposed to primary effusion 
lymphoma), anemia, thrombocytopenia, lymphadenopathy and splenomegaly 
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(reviewed in Polizzotto et al, 2012). An alternative clinical diagnosis is that of 
Systemic Inflammatory Response Syndrome (SIRS). SIRS can cause rapid 
death in AIDS patients. It is thought of as an extreme, uncontrolled, cytokine-
mediated response to infection in CD4 deficient patients. The underlying trigger 
of this response is typically unknown. Thus, symptomatic treatment remains the 
only option. 
KSHV inflammatory cytokine syndrome (KICS) has been recently been 
proposed as a new KSHV associated disease (Uldrick et al., 2010).  The six 
patients originally described had no evidence of MCD despite thorough 
examination, and no development of MCD upon follow up.  However, they 
presented with clinical inflammatory syndromes as seen in MCD, high human IL6 
levels, and high systemic KSHV viral load.  The patient described here had the 
highest systemic KSHV viral load on record to date, with no identifiable MCD. He 
fits the novel clinical description for KICS and we were able to establish the 
complete DNA vironome from blood.  
Systemic KSHV – HHV6a co-infection was uncovered by next generation 
sequencing of peripheral blood mononuclear cells and plasma. We obtained a 
complete KSHV genome sequence from high titer, replicating virus rather than 
tumor associated or tissue culture propagated variants (Depledge et al. 2011, Lin 
et al. 2012), which in the case of KSHV tend to replicate extremely poorly and 
may have accumulated mutations.  
 
 
 105 
METHODS 
DNA Extraction 
 Genomic DNA was isolated from white blood cells or plasma using Wizard 
SV™ kit (Promega Inc.). All PCR products were of the expected size by gel 
electrophoresis. No amplification was observed without template.  Detailed 
methods were published previously (Chugh et al., 2010, Dittmer, 2011).  The 
primer sequences were: (LANA78 5’- GGAAGAGCCCATAATCTTGC, 5’-
GCCTCATACGAACTCGAGGT (204 bp); KS10076-1 (vFLIP) 5’- 
ATGCCCTAATGTCAATGCTT, 5’- GCGATAGTGTTGGGAGTGTG (90 bp); 
K14F 5’-TGGTGGGCCTATTTGGGATA, 5’- GATGCACCGCCCTGCTT (60 bp); 
orf74F-spl (vGPCR) 5’-TGGCCCAAACGGAGGATCCTAG, 5’-
GATGATGAATCCTGGAATGAAACT (232 bp); kaposin 5’- 
CAACAGATAATGGGCCTTGT, 5’- AGGTGCAAGCAGACATAATTG ; ORF69  
5’-TGCAGTGCAGGTACACACCA, 5’-GCATCTCGTCGGTGCAGTCT (61 bp); 
hu-gapdhF 5’-GAAGGTGAAGGTCGGAGTC, 5’-GAAATCCCATCACCATCTTC 
(225 bp) . Amplicon sizes are based on alignment to HHV8 reference genome 
NC_009333 and   NM_002046 for gapdh. 
 
Illumina Sequencing 
 Illumina™ sequencing was performed by sonication of DNA, primer 
ligation and tethered amplification, followed by DNA synthesis to yield 35 base 
reads. The high viral load allowed us to use total DNA without virus-specific 
enrichment (e.g. Kwok et al. 2012). To prepare the library, DNA was sonicated, 
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then ends were repaired and adenylated.  Paired end adapters were ligated to 
DNA fragments and purified via gel electrophoresis excision and QIAGEN Gel 
Extraction Kit (QIAGEN, part #28704).  Ligated products were amplified using 
PCR prior to sequencing run.   Sequencing was performed using a variety of 
conditions: Paired end 2x76 cycles.  Additional runs include 50bp single reads, 
36 bp paired reads, and 76bp single reads. The reads were aligned to human, 
viral (Genbank ID: NC_003409 for KSHV, NC_001664 for HHV6a) and microbial 
genomes using CLCbio software (CLCbio Inc.) and EMBOSS (Rice et al., 2000). 
By computing the number of sequence reads that aligned to a given 
pathogen genome against the genome size, we estimated the relative frequency 
of the pathogen. For human DNA, we obtained on average 0.005 reads/ bp; 
more for mitochondrial genomes, since there are multiple mitochondria per cell 
genome. For KSHV and for HHV6a we obtained almost equal coverage with 
0.003 reads/ bp. In contrast, HHV6b coverage was 10 fold lower (5x10-4 
reads/bp), as was EBV (3x10-5 read/ bp) and (HCMV 8x10-6 read/ bp) coverage.   
Our discovery score D takes is a linear combination of the number of hits, the 
target genome and coverage. It was calculated for each genbank entry and each 
sample and subjected to unsupervised clustering using R v2.8.0 (Maindonald 
and Braun, 2007).  
 
Phylogenetic Comparison 
To compare our KSHV isolate to existing whole genome data, we used clustalW 
and the following sequences: BCBL1 (Genbank ID: HQ404500), JSC1 (Genbank 
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ID: GQ994935), KS biopsy (Genbank ID: U93872), BC1 (Genbank ID: 
KSU75698), and GK18 (Genbank ID: NC_009333).  Our patient sequence is 
indicated as Consensus and submitted as Genbank ID: JQ619843. 
 
Immunohistochemistry 
A formalin-fixed, paraffin-embedded lymph node was sectioned and 
dehydrated through a series of ethanol washes.  Sections were then stained 
using a rat monoclonal anti-LANA antibody (Advanced Biotechnologies Inc.) 
diluted at 1:1000, and Vectastain™ (Vectorlabs Inc.) kit, counterstained with 
hematoxylin, and rehydrated through a series of xylene washes before being 
fixed with a xylene-based mounting solution.  Images were collected on a LEICA 
DM LS microscope with DFC480 camera. 
 
RESULTS 
The patient is a 42-year old Caucasian male who was diagnosed with 
human immunodeficiency virus (HIV) infection in 1993 and treated with 
zidovudine/lamivudine and nevirapine.  He discontinued medication in 2003, 
when his HIV-1 viral load was undetectable. He presented in December 2008 
with a HIV-1 viral load of 600,000 copies/ ml and a CD4 count of 27 cells / µl, and 
met the clinical criteria for SIRS. The definition of SIRS is based on clinical 
parameters of systemic inflammation not unlike KICS, but typically does require 
an association with a specific infectious agent.  
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First, we tested for the presence of typical infectious agents. Stool for 
clostridium difficile and sputum for pneumocystis jirovecii were negative.  
Serology studies for cryptococcus, toxoplasma, mycobacteria, and syphilis as 
well as urine histoplasma antigen were also negative. Epstein-Barr-virus loads 
(EBV) and human cytomegalovirus loads (HCMV) were negligible with < 250 
copies/ml and 647 copies/ml, respectively.  The IL6 level was 54.1 pg / ml. In the 
absence of AIDS defining infections (and of CD4 T cells), we asked why would 
this patient show evidence of a severe, systemic inflammatory reaction?   
Excisional axillary lymph node biopsy showed effacement of the expected 
architecture, with general lymphocyte depletion, increased numbers of mature-
appearing interfollicular plasma cells, and disrupted lymphoid follicles typical of 
HIV lymphadenitis (histologic pattern B). There were no aggregates of 
plasmablastic mononuclear cells. Moreover, reactive germinal centers and those 
showing hyaline vascular Castleman features were not identified. Kappa and 
lambda in situ hybridization demonstrated overall polytypic staining of the plasma 
cells, and no monoclonal B cell population was identified by thorough flow 
cytometric analysis. Thus, lymphoma and multicentric Castleman disease (MCD) 
were excluded. KSHV latency associated nuclear antigen (LANA) expression 
was largely confined to the residual follicles, in contrast to the pattern observed in 
MCD (Figure 4.1, panel A and B) (Chadburn et al. 2008, Schmidt et al. 2008).  
Lambda light chain staining showed overlap with LANA localization, consistent 
with recent reports that suggest preferential KSHV infection of lambda-
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expressing B cells  (Hassman et al, 2011). No overlap of EBV EBER and KSHV 
LANA expression was observed. 
The patient ultimately died of disease-related complications. Autopsy 
confirmed KS of the oral mucosa, skin, small bowel, and lung (Figure 4.1, panel 
C, D). However, KS could not explain the massive hepatosplenomegaly, severe 
anemia and thrombocytopenia thought to be secondary to sequestration. 
The presence of KSHV in plasma was initially detected by DNA PCR 
using primers directed against multiple regions of the viral genome, specifically 
the open reading frames LANA, vFLIP, vGPCR, Kaposin and orf69 (Figure 4.1, 
panel E). We chose multiple genes to increase the specificity of our assay. These 
primers were previously validated on clinical and experimental samples (Dittmer, 
D.P., 2011, 2003). As positive control for DNA isolation from clinical specimens 
we used gapdh primers. The positive control was total DNA from BCBL-1 cells 
and the negative control sample was water. All primers amplified the predicted 
size fragment from the patient sample and positive control, but not the negative 
control (the very faint bands in lane 1 and 3 represent primer dimers, which were 
smaller than the predicted size).  No band was observed in the ‘no primer control’ 
lane (Figure 4.1, panel E, lane “.”). As this assay is a conventional endpoint PCR 
assay, it is not quantitative. The brightness of the individual bands is dependent 
on their size as well as accumulation.  The three longest PCR products 
correspond to KSHV genes LANA, vGPCR and gapdh (Figure 4.1, panel E, lanes 
1, 4, “+”). The four very short PCR products yielded shorter and thus less bright 
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products (Figure 4.1, panel E, lanes 2, 3, 5, 6). This demonstrates that KSHV 
was present in PBMC of this patient. 
To detect free virus, we determined the plasma viral load of KSHV. The 
patient had a plasma KSHV viral load of 5,300,000 copies/ml (Viracor-IBT 
Laboratories, MO).  This represents the highest KSHV viral load on record (Table 
4.1).  By comparison KS patients (Polstra et al., 2003, Sayer et al., 2011) 
typically have a mean KSHV viral load of 1000 copies / ml (range 151 - 26,915), 
PEL patients (Simonelli et al., 2009) of 10,284 copies / ml (range 2,558 - 36,300) 
and MCD (Simonelli et al., 2009) of 4,400 copies / ml (range 600 - 1,678,000).  
KS malignancies are AIDS defining, but rarely associated with high-level virus 
replication.  Average KSHV plasma viral loads are 1-2 log10 units lower than EBV 
or HCMV viral loads even in symptomatic patients (Laney et al., 2007, Whitby et 
al., 1995).  Hence, for this exceptional case we considered that the patient 
succumbed to acute KSHV viremia. 
We turned to Illumina-based sequencing to determine the complete 
vironome and complete genome sequence of this KSHV isolate. Total DNA was 
isolated from white blood cells. No attempts were made to enrich for viral 
sequences. Illumina™ sequencing was performed by sonication of DNA, primer 
ligation and tethered amplification, followed by DNA synthesis to yield >35 base 
reads.  To determine the vironome, sequencing reads were aligned to the 
reference genomes of all known viruses. Combining 5 individual sequencing runs 
we obtained a total of 145,179,479 reads of 36 bp (paired), 50bp (single) and 75 
bp (paired and single) from samples of this patient. A discovery score (D score) 
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based on the total number of aligned reads and coverage for each viral genome 
was computed and subjected to hierarchical clustering.  Sequencing reads from 
samples of known herpesvirus genome status (two copy EBV - integrated cell 
line Namalwa, PEL cell line BCBL-1) were included to calibrate the virus 
discovery algorithm. In four of the sequencing runs for this patient, purified 
Guinea Pig CMV DNA was spiked in as an internal control, and was recovered in 
sequence alignment for these samples (Genbank ID: AB592928).   
The clustering results are displayed as heatmap and dendrograms (Figure 
4.2, panel A). Positivity is displayed as by color (white, orange, red), with deeper 
red color indicating a higher D score.  D score is a weighted combination of 
coverage, genome-size and number of hits.  For the 24 human chromosomes we 
calculated at 95%CI of -0.03 to 0.07 log10 copies/ cell, i.e. two copies per cell. Our 
initial screen identified sequences for 648 genbank entries, which were classified 
as either fungal, viral, protozoal or bacterial. However, most were present at ≤ -2 
log10 genome copies/ cell, i.e. fewer than 1 copy per cell. Several bacterial 
pathogens, including toxoplasma, were tested for, but could not be confirmed by 
standard tests. Mitochondrial genomes were present at 1.52 log10 copies/ cell, 
and KSHV was present at 0.23 log10 copies/ cell, i.e. at > 1 copy per cell. 
In total, 22,455 reads aligned to KSHV, resulting in a 9.23 fold median 
genome coverage (Figure 4.2, panel B).   The presence of HHV6a (but not 
HHV6b or HHV7) was also revealed upon sequence analysis.  This was 
surprising, as infection with HHV6a was never suspected or tested for.  Upon 
retesting of patient plasma we determined the HHV6 viral load to be 25, 471 
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copies/mL.  We have investigated the presence of HHV6 (a or b) in 17 additional 
HIV patients. 5 of these patients had KS, while the remaining 12 were KS 
negative, but positive for another type of malignancy.  None of the patients were 
positive for HHV6a, and 1 patient was positive for HHV6b, with approximately 
1000cp/mL.  This patient was KS negative, and was positive for Melanoma, a 
non-AIDS defining malignancy.  This is consistent with the prevalence in the 
general population, where HHV6b is much more common than HHV6a, which is 
rarely found in patients (Boutolleau et al., 2006). 
A total of 23,300 reads mapped to HHV6a, yielding 7.65-fold median 
coverage (Figure 4.2, panel C).  Since coverage is a function of copy number 
and genome size this demonstrates for the first time HHV8 and HHV6a co-
replication in a patient.  Both KSHV and HHV6a DNA sequences were found in 
roughly equal proportion in cell-free plasma, where the KSHV plasma viral load 
was > 106. This would argue that the HHV6a signal, too, stemmed from 
replication virus rather than being horizontally transmitted. 
We established uniformity of genome coverage as a second criterion for 
virus identification.  All reads mapped randomly across the entire length of the 
HHV8 and HHV6a genomes (Figure 4.2, panel B, C). Reads that aligned to more 
than one position, i.e. to repeat region, were randomly placed at only a single 
position. In contrast to HHV6a, the few reads that mapped to HHV6b genome, all 
clustered within the terminal repeat region (data not shown), indicating 
insufficient coverage to demonstrate biologically relevant infection.  
 113 
We derived the whole genome sequence for this KSHV strain by 
reference-guided assembly (Genbank ID JQ619843). The KSHV consensus 
sequence was compared to the KSHV reference sequence (Genbank ID: 
NC_009333). We did not identify novel DNA insertions or orfs. We identified 
small InDels in specific genes (the polymorphic regions of K1 and K15) and in 
repeat regions, which is a result of the short read length of the Illlumina platform, 
but not deletions of entire coding regions or gross aberrations. Thus no one gene 
could be linked to the highly replicative phenotype. These are annotated in the 
sequence submission. 
To demonstrate relatedness of this primary KSHV isolate to tumor cell line 
derived viral sequences, we used ClustalW (Felsenstein, 1989) using bootstrap 
analysis with Neighbor-Joining. The pairwise distances between all the aligned 
whole genome sequences were computed using a maximum likelihood model, 
the number of replications for bootstrap analysis was 1000.  The result is 
displayed using PHYLIP (R Development Core Team, 2012) and demonstrated 
high sequence conservation expected of double-stranded DNA viruses (Figure 
4.2D).  This is the sequence of a primary, highly replicative KSHV isolate.   
It is difficult to derive genome-wide conclusions from a comparison of just 
six genomes.  We did note extraordinary conservation in primary nucleotide and 
amino acid sequences among all isolates. For the unique regions of the genome, 
approximately one nucleotide change was present per kb and less than one 
amino acid per coding regions, as expected for DNA viruses. The most divergent 
sequence was the original BC-1, which was obtained by Saenger sequencing; 
 114 
and which may not have had the extensive genome coverage afforded by 
NextGen based sequencing.  The Sau3AKS sequence has deletions in K15 
compared to all other sequences, which may be the result of phage library prep 
and propagation in E.coli. We observed variations and gaps in the repeat regions 
(LIR1, DR1-6, and TR). These could be the result of misalignment, as short read 
– based protocols are known to generate incomplete alignments in repeat 
regions, or they could be the result of genome evolution. For instance, a 36 bp 
gap in K1 was conserved in this sequence, GK18, JSC1 and Sau3A; a 9bp 
deletion in DR3 was conserved in JSC1, BCBL1 and Sau3A.  We did not have 
enough coverage for a de-novo assembly to unambiguously identify small DIPs 
or SNPs for this particular isolate. 
Rather than directly testing for each potential pathogen sequentially, 
NextGen sequencing technology allowed us to detect a broad range of viruses, 
bacteria, fungi, and parasites, resulting in the detection of additional factors that 
may be playing a role in the disease - in this case, HHV6a.  
 
DISCUSSION 
This report highlights NextGen sequencing technology on patient material 
to identify infectious agents in a case of fatal inflammation reaction of unknown 
origin.  Rather than testing for each potential pathogen individually, sequencing 
of total DNA in plasma and PBMC allowed us to screen for a broad range of 
viruses, as well as bacteria, fungi, and parasites (data not shown), thus resulting 
in the detection of additional factors that may be playing a role in patient illness- 
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in this case, HHV6a viremia.  This novel application of Illumina sequencing to 
assist in patient diagnosis proved to be a useful tool in determining the cause of 
illness and death in this patient. 
This represents the first documentation of systemic KSHV/HHV6 co-
replication in a patient. Primary HHV6 infection is mostly subclinical and HHV6 
has near 100% sero-prevalence in the US.  HHV6a is primarily associated with 
exanthema subitum (Roseola). It has been detected in end-stage AIDS patients, 
but these instances are extremely rare.  HHV6a DNA has been detected in a 
single archival case of a PEL biopsy before (Asou et al., 2000) but not as free, 
replicating virus.  HHV6a is also found in forms of reactive lymphoid hyperplasia, 
such as Crohn’s disease, histiocytic necrotizing lymphadenitis or Kikuchi-
Fujimoto disease in high prevalence areas, although present studies are 
insufficient to support a conclusive association of HHV6a with these or other 
forms of rare reactive lymphoid hyperplasia (Bouvard et al., 2009).  HHV6a can 
cause KSHV reactivation from PEL cell lines in culture, as can HCMV (Lu et al., 
2005, Vieira et al., 2001).    
Whether, in turn, KSHV can stimulate HHV6a replication and/or its 
pathogenesis is presently unknown. Both viruses encode as well as induce 
cytokines and chemokines, including human IL6 and vIL6, which can induce 
inflammatory symptoms. We surmise that systemic replication of both viruses, 
rather than KSHV-associated neoplasia, led to the clinical symptoms.  The 
clinical description of SIRS as a cytokine storm is consistent with that of KICS, 
which was recently proposed as a new KSHV associated clinical entity and which 
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is defined by high cytokine production, particularly of IL-6 and the presence of 
KSHV, but a negative diagnosis for MCD. We propose that co-infection may have 
added to the intensity of KICS.  Further studies are necessary to assess whether 
HHV6a co-infection is present in other KICS patients, or if it is necessary for the 
development of KICS.  
 
CONCLUSIONS 
We have described a fatal case of systemic KSHV and HHV6a co-viremia 
in an AIDS KICS patient. Using Next generation sequencing, we were able to 
generate the first KSHV sequence directly from patient sample, without 
implementing cloning techniques.  This novel sequence has been deposited into 
Genbank.  
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TABLES AND FIGURES 
 
 
 
FIGURE 4.1: Patient was positive for Kaposi Sarcoma, as confirmed 
by autopsy, immunohistochemistry, and PCR 
 
 
 
(A) LANA (red) and hematoxilin (blue) stain of a lymph node biopsy at 100x, (B) 
and at 400x.  (C-D, arrows) KS lesions in lung at autopsy, (E) Gel of PCR 
products confirming KSHV positivity.  Isolated PBMC DNA was amplified with 
primers located within the KSHV genes: (1) LANA, (2) vFLIP, (3) K14, (4) 
vGPCR, (5) Kaposin, (6) Orf69 and GAPDH (“+”) as a reference gene.  No primer 
controls for each sample are indicated by “.”  For comparison, KSHV positive 
PEL DNA was used (“pos”), and a non-template control (NTC) was included as a 
negative control (“neg”).  Molecular weight markers are shown at the beginning 
and end. 
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TABLE 4.1: Comparison of viral loads for KSHV-associated diseases, 
as compared to this case. 
 
 
 
 
 
 
 
 
 
a:  KS, Kaposi sarcoma, (Polstra et al., 2003) 
b:  PEL, primary effusion lymphoma, MCD, multicentric Castleman disease, 
(Simonelli et al., 2009) 
 
 
Disease	   Min	  (copies/mL)	   Max	  (copies/mL)	   Mean	  (copies/mL)	  
KSa	   151	   26,915	   1,000	  
PELb	   2,558	   36,300	   10,284	  
MCDb	   600	   1,678,000	   4,400	  Patient	   -­‐	   -­‐	   5,300,000	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FIGURE 4.2: Nextgen sequencing analysis reveals KSHV and HHV6a 
co-infection 
 
 
 
(A) Heatmap and dendrogram of unsupervised single linkage clustering using a 
Manhattan distance matrix.  Reads from individual Illumina lanes were aligned to 
3608 whole viral genomes in genbank. For each alignment we computed a score 
based on the number of hits, coverage and length of the target sequence. (B) 
Distribution of reads that aligned to the KSHV (NC_003409) genome. Open 
reading frames are depicted as arrows. (C) Distribution of reads that aligned to 
 120 
the HHV6a (NC_001664) genome. (D) Phylogenetic tree demonstrating 
alignment of generated consensus sequence for KSHV isolated from patient 
PBMC, in comparison to previously reported KSHV sequences.   BCBL1 
sequence was determined from BCBL1 DNA inserted into BAC36 and cloned.  
GK18 sequence is from cosmid-cloned DNA originating from a classic KS 
patient.  JSC1 sequence is derived from cellular DNA cloned into BAC219.  KS 
biopsy sequence is derived from DNA from KS biopsies, partially digested with 
Sau3A, cloned into lambda phage, and sequenced.  BC1 DNA was sequenced 
from the PEL-derived cell line, and was cloned into lambda phage and cosmids 
and sequenced.  Our patient sequence is indicated as Consensus.  
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CHAPTER V. 
OVERVIEW OF FINDINGS AND FUTURE DIRECTIONS 
 
CHAPTER II: ART NAÏVE KAPOSI SARCOMA (KS) PATIENTS 
EXPRESS KSHV ORF21 AND ORF36 AND MAY BENEFIT FROM 
GANCICLOVIR THERAPY– AN AIDS MALIGNANCY CONSORTIUM 
STUDY (AMC-S001) 
 The potential efficacy of treating therapy-naïve KS patients with the drug 
ganciclovir (GCV) was assessed by looking directly at the expression of GCV-
activating KSHV genes in tumor biopsies.  This direct approach enables us to 
answer a fundamental question: Is a population of ART-naïve HIV-positive KS 
patients potentially able to activate the GCV, and therefore benefit from its 
administration?  While previous work has shown that lytic-expressed KSHV 
kinases Orf21 and Orf36 can activate GCV to its functional form in vitro (Cannon 
et al, 1999; Davis et al., 2007), no studies have looked directly in the tumor 
biopsies for these genes.  Additionally, GCV was not proven to be effective 
treatment in a recent study of classic KS patients, and post-study analysis 
revealed a lack of lytic KSHV gene expression, hinting at the inability to activate 
GCV to its functional form (Krown, Dittmer, and Cesarman, 2011).  Therefore, it 
is not that this treatment does not work, but more careful stratification is 
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necessary to only give GCV to KS patients with high levels of lytic gene 
expression.   
In this study, we aimed to profile the population of therapy-naïve HIV-
positive KS patients in Malawi, and found the 78% of tumor biopsies 
demonstrated expression of these essential viral kinases.  This serves as 
preliminary evidence justifying future studies in this field.  Specifically, this pilot 
study sets the stage for an interventional clinical trial where newly-diagnosed KS 
patients can be stratified by tumor kinase gene expression and treated with GCV. 
This would more directly test whether patients from whom we found expression 
of viral kinases are able to respond to GCV, as opposed to patients without 
kinase expression.  While geographically this study can technically be designed 
to enroll anywhere, Malawi would be an excellent candidate location due to the 
high numbers of previously undiagnosed KS patients that present to the 
Lighthouse Clinic.  An additional aim of this new study could be to ascertain 
whether expression of both viral kinases are important, or if one kinase is 
sufficient to confer drug activation.  In vitro work has demonstrated the Orf 36 is 
more effective in its ability to phosphorylate GCV (Cannon et al., 1999), and it 
would be interesting to note whether this remains true in vivo.  As the pilot study 
that provided these samples was funded by the AIDS Malignancy Consortium, I 
have high hopes that these strong findings will yield a future clinical trial more 
directly assessing the benefits of patient treatment stratification based on viral 
kinases gene expression.  
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CHAPTER III: VARIATION IN GENE EXPRESSION PROFILE 
DISTINGUISHES SUBTYPES OF KAPOSI SARCOMA TUMORS 
 The next part of my thesis expanded on the premise of profiling tumor 
biopsies proposed in Chapter II.  Rather than assessing the expression of viral 
kinases, this chapter aimed to profile genome-wide KSHV transcription in KS 
tumor biopsies from the same cohort in Malawi.  We concluded that patients 
could be stratified into two groups- those with and those lacking genome wide 
KSHV transcription.   
One important observation is that in the subgroup of patients who had 
evidence of genome-wide transcription, CD4 counts were higher.  While this 
finding was not statistically significant, it is unclear whether this analysis was 
limited by the small sample size.  Therefore it would be interesting to use future 
studied to observe whether this finding holds true.  
Additionally, while it is clear that two groups can be distinguished based 
on gene expression profiles, what remains unclear is the implications that 
subgroup classification may have clinically. Do patients lacking genome-wide 
transcription have a better prognosis? Are tumors that demonstrate genome- 
wide transcription more likely to developed in more advanced nodule lesions? 
Might these patients respond differently to treatment? Based on evidence 
demonstrated in Chapter 2, there may be evidence that patients with lytic 
transcription could respond to therapies that would be futile in patients lacking 
transcription (ie- Orf21 and Orf36 in the case of ganciclovir).  However, this 
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finding may be extended not only to KS treatment plans, but it is also possible 
that one subgroup may demonstrate variable response to HIV HAART.  
Another important question that we were unable to address here but may 
be critical to furthering our understanding: How do individual lesions in a single 
patient vary?  It is possible that this result does not reflect two different 
subgroups of patients, but rather two different types of lesions that may exist in a 
single patient.  That is, it can be excluded that individual patients may have 
several lesions demonstrating each type of gene expression profile observed in 
this study, and that the stratification is dependent on the lesion that was selected 
for biopsy.  This could be addressed by comparing gene expression profiles from 
multiple biopsies from a single patient.  Unfortunately, this study only obtained a 
single lesion from each patient and therefore this questions remains 
unanswerable.  A novel study is necessary to address this question, and it is 
unclear whether this is feasible in patients, as patients may not consent to 
multiple biopsies for the sake of research. While the research in this chapter 
provides a depiction of the types of expression profiles observed in KS tumor 
biospies, it also open up many more questions in the field that hopefully can be 
the focus of future work.  
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CHAPTER IV: VIRONOME OF KAPOSI SARCOMA-ASSOCIATED 
HERPESVIRUS-INFLAMMATORY CYTOKINE SYNDROME IN AN AIDS 
PATIENT REVEALS CO-INFECTION OF HUMAN HERPESVIRUS 8 AND 
HUMAN HERPESVIRUS 6A 
 This chapter describes a case study of an HIV-patient for whom a clear 
diagnosis was clinically unattainable.  End-stage AIDS is frequently complicated 
to diagnose, as many factors must be considered including compromised 
immune status and the presence of co-infections. Here, we used next-generation 
sequencing to directly assess the underlying co-infections present in a patient. 
This resulted in a complete profiling of co-infections, which in this case revealed 
high levels of KSHV and HHV6a viremia.  While using sequencing clearly 
represents a direct method of testing for infections rather than using individual 
tests targeting one infectious agent at a time, it is important to note a critical 
limitation.  Sequencing is currently not a feasible option for the clinic, as it is 
expensive and results are not obtained in a clinically relevant time period.  
However it is possible that as technology improves, we may no longer be limited 
by these barriers.   
 The finding of high HHV6 viremia in this KICS patient is interesting.  KICS 
is a very newly described KS-associated condition characterized by systemic 
high-level KSHV viremia, coupled with elevated inflammatory markers (Uldrick et 
al., 2010a, Uldrick et al., 2010b).  The definition of this disease is new, and 
therefore not much is known about the condition.  The presence of HHV6a co-
infection in other KICS patients has not been assessed and therefore cannot be 
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excluded.  Although it is not possible to draw such vast conclusions on the basis 
of a single case, it would be interesting to determine if this finding is unique to 
this case or commonplace in KICS.  
 Lastly, it is important to note that at first pass, sequencing did not reveal 
any obvious KSHV sequence deviations that might contribute to the high viremia 
observed in this patient.  For example, all ORFs appeared to be present, with no 
large gaps or mutations in transcription start sites. However, more thorough 
analysis of KSHV sequence is currently underway, and it is possible that a SNP 
or other mutation may be attributed to the high viral load in this patient despite 
minimal KS lesions.  Additionally, it is also possible that a host mutation may be 
responsible for allowing the virus to replicate to such high copy numbers, 
although this may be much more difficult to address given the size of the human 
genome. One potential method to distinguish between whether viral or host 
factors may be playing a role in the apparently uninhibited viral replication would 
be to observe how cells infected with KSHV isolated from this patient grow in 
culture.  Unfortunately, attempts to isolate KSHV from this patient were futile, and 
a lack of additional sample indicates that we may never be able to answer this 
question for this case.  
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APPENDIX I: 
PROFILING OF PRE-MICRO RNAS AND MICRO RNAS USING 
QUANTITATIVE REAL-TIME PCR (QPCR) ARRAYS 
 
 
 
PREFACE 
 This work has been published with accompanying video article in the 
Journal of Visualized Experiments (JoVE) in 20105.  This work represents a 
collaboration between myself and my co-first author and labmate Dr. Pauline 
Chugh.  Together, we developed the methods described, drafted the manuscript, 
performed the experiments, created the figures, and demonstrated the 
experiments in the video.  Dirk Dittmer was the principle investigator of the study, 
and oversaw the project and assisted with the manuscript and video preparation.  
 The video component of this article can be found at 
http://www.jove.com/details.php?id=2210. 
 
 
 
 
 
________________________________________________________________ 
5 Tamburro, K., Chugh, P, Dittmer, D.P. Profiling of Pre-microRNAs and microRNAs 
using Quantitative Real-time PCR (qPCR) Arrays. Journal of Visualized Experiments, 
2010.  
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INTRODUCTION 
Quantitative real-time PCR (qPCR) has emerged as an accurate and 
valuable tool in profiling gene expression levels.  One of its many advantages is 
a lower detection limit compared to other methods of gene expression profiling 
while using smaller amounts of input for each assay.  Automated qPCR setup 
has improved this field by allowing for greater reproducibility.  Its convenient and 
rapid setup allows for high-throughput experiments, enabling the profiling of 
many different genes simultaneously in each experiment.  This method along 
with internal plate controls also reduces experimental variables common to other 
techniques.   
We recently developed a qPCR assay for profiling of pre-microRNAs  (pre-
miRNAs) using a set of 186 primer pairs (O'Hara et al., 2009a; O'Hara, Vahrson, 
and Dittmer, 2008; O'Hara et al., 2009b). MicroRNAs have emerged as a novel 
class of small, non-coding RNAs with the ability to regulate many mRNA targets 
at the post-transcriptional level.  These small RNAs are first transcribed by RNA 
polymerase II as a primary miRNA (pri-miRNA) transcript, which is then cleaved 
into the precursor miRNA (pre-miRNA).  Pre-miRNAs are exported to the 
cytoplasm where Dicer cleaves the hairpin loop to yield mature miRNAs.  
Increases in miRNA levels can be observed at both the precursor and mature 
miRNA levels and profiling of both of these forms can be useful.  There are 
several commercially available assays for mature miRNAs; however, their high 
cost may deter researchers from this profiling technique.  Here, we discuss a 
cost-effective, reliable, SYBR-based qPCR method of profiling pre-miRNAs.  
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Changes in pre-miRNA levels often reflect mature miRNA changes and can be a 
useful indicator of mature miRNA expression.  However, simultaneous profiling of 
both pre-miRNAs and mature miRNAs may be optimal as they can contribute 
nonredundant information and provide insight into microRNA processing.  
Furthermore, the technique described here can be expanded to encompass the 
profiling of other qPCR library sets for specific pathways or pathogens.   
 
METHODS 
The qPCR pre-miRNA profiling arrays can be set up as fully automated 
with a Tecan Freedom Evo robot (A) or semi-automated with the Matrix 
electronic multichannel pipette (B). 
1) Prepare the master mix, primer plates and samples. 
1.1. Primer plates containing 186 primer pairs in 96-well format (total of 
2 plates) at 0.5pM should be stored at -80°C.  Thaw plates out at 
room temperature, vortex and centrifuge briefly before use.   
1.2. To prepare the master mix, thaw out SYBR Green 2x PCR Mix at 
room temperature.  Each reaction uses 8µl master mix with 2µl 
primer. The composition of the master mix per reaction is 4µl SYBR 
mix, 3µl PCR grade water and 10-20ng sample DNA or cDNA.  
1.3. For setup of each 96-well primer plate, four master mix tubes will 
be needed.  Samples can be run 4 samples per plate (singlicate), 2 
samples per plate (duplicate) or a single sample in quadruplicate.   
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1.4. Prepare master mix by combining SYBR, water and sample in each 
of 4-2ml Eppendorf tubes.  Each tube should contain enough 
master mix for approximately 100 reactions, allowing excess for 
pipetting waste.  Vortex to mix. 
 
A. SETUP OF PRE-MIRNA ASSAY USING THE FREEDOM TECAN EVO 
ROBOT 
2.1. Following initialization of the robot and loading of the Evoware program, 
flush three times with 30mls each to clear system of air bubbles that will interfere 
with pipetting accuracy.   
2.2. Setup the robot platform to include the following: 
 -Labeled 384-well plate 
 -96-well primer plate (1) 
 -Master mixes 
 -A trough containing 2% bleach 
 -A filled system fluid container 
 -Empty waste container 
2.3.  Begin automated robot run by selecting “Run” twice.   
2.4.  At end of program, remove 384-well plate and seal with LightCycler 480 
sealing foil and centrifuge briefly.  Place sealed 384-well plate in position 1 of the 
hotel. 
2.5.  Go to step 2.2 and repeat for primer plate 2 with new master mixes and a 
new 384-well plate.   
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 2.5.1. Place sealed plate in position 2 of the hotel. 
2.6. Open new Evoware program for Loading the Lightcycler from the hotel and 
select “Run” twice. 
2.6.1. Freedom Evo will automatically load each plate into the 
LightCycler and run the following SYBR-green I/HRM cycling 
program: 
 
Pre (1 cycle):  50° for 5 minutes at ramp rate of 4.8°/sec 
     95° for 5 minutes at ramp rate of 4.8°/sec 
  Amp (45 cycles):  95° for 15 sec at ramp rate of 4.8°/sec 
     62° for 30 sec at ramp rate of 2.5°/sec 
     (Single data acquisition during this step) 
  Melting curve:  95° for 5 sec at ramp rate of 4.8°/sec 
     60° for 1 minute at ramp rate of 2.5°/sec 
     95° continuous at ramp rate of .11°/sec 
     with 5 acquisition per °C 
  Cool :    50° for 30 sec at ramp rate of 25°/sec 
 
 
B. SETUP OF PRE-MIRNA ASSAY USING THE MATRIX 
ELECTRONIC MULTICHANNEL PIPETTE 
3.1.  Place contents of master mix tube 1 into a reservoir.   
3.2. Set the electronic pipette to aspirate 16µl of master mix with 2-8µl dispense 
steps followed by a purge step. 
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3.3. For master mix 1, dispense 8µl into every other well of the 384-well plate (set 
on 384-well tip spacing), beginning with well A1. (i.e. wells A1, C1, E1, etc.) For 
the second 8µl dispense, move to column 3 (i.e. wells A3, C3, E3, etc.) then 
purge over a waste container and dispose tips. 
3.4. Follow this pattern for the remaining 5 cycles until you reach well A23. 
3.5. Repeat for master mix 2, (beginning with well A2, C2, E2, etc.); master mix 3 
(beginning at well B1, D1, F1, etc.); master mix 4 (beginning at B2, D2, F2, etc.). 
3.6. For aliquotting of primer plate, set electronic pipette to aspirate 2µl and 
dispense 2µl with a purge step following.  Dispense 2µl of primers from column 1 
of 96-well primer plate (A-H) into the 384-well plate, wells A1, C1, E1, etc.  Purge 
over a waste container and dispose tips.  Repeat for wells A2, C2, E2; B1, D1 
,F1; and B2, D2, F2, etc. 
3.7. Repeat for rows 2-12 of 96-well primers, moving over every 2 columns for 
each primer column, until full 384-well plate has been aliquotted. 
3.8. Seal plates with a LightCycler sealing foil and centrifuge briefly. 
3.9. Place plates into a LightCycler 480 and cycle the plates according to the 
following settings using the SYBR Green I/HRM detection format: 
 
Pre (1 cycle):  50° for 5 minutes at ramp rate of 4.8°/sec 
     95° for 5 minutes at ramp rate of 4.8°/sec 
  Amp (45 cycles):  95° for 15 sec at ramp rate of 4.8°/sec 
     62° for 30 sec at ramp rate of 2.5°/sec 
     (Single data acquisition during this step) 
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  Melting curve:  95° for 5 sec at ramp rate of 4.8°/sec 
     60° for 1 minute at ramp rate of 2.5°/sec 
     95° continuous at ramp rate of .11°/sec 
     with 5 acquisition per °C 
  Cool :    50° for 30 sec at ramp rate of 25°/sec 
3.10. Repeat using primer plate 2, aliquotting into a fresh 384-well plate 
using freshly prepared master mixes. 
 
SECRETS TO SUCCESS 
• An important characteristic when designing PCR arrays is that all 
186 primer pairs have the same annealing temperature, so the 
plate can be run at the same optimal PCR run program settings. 
• Each new array should be checked using three controls prior to 
running samples.  These controls are: 
o 1 run of all primers run with water or .1x TE to rule out primer 
contamination. 
o 1 run of alternating water/TE and positive control, to ensure 
no carryover. 
o 3 runs using the same positive control, to ensure 
reproducibility between runs.  
• Master mixes should be freshly prepared, and plates should be run 
within 24 hrs for optimal results 
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• Primer plate foil should be removed slowly to reduce risk of 
contamination between wells.  
• When using a robot with fixed tips, 2% bleach wash is necessary to 
wash the tips between each pipetting step, followed by a water 
flush.  This prevents and eliminates carryover, which could 
otherwise contaminate data and lead to inconclusive results. 
• After a plate is run through the Lightcycler, it should not be opened 
again in the PCR setup room. This helps prevent PCR 
contamination.   
 
 
 
REPRESENTATIVE RESULTS   
qPCR results are typically represented by CT values as determined from 
the Lightcycler analysis software.  A successful run usually consists of a range of 
CTs for samples, typically between 20-35 for samples that are positive.  The 
water samples in a good run are always at a CT of >40 and any samples or 
specific wells with a CT over 37 are considered negative or not detected.  As a 
general rule, samples yielding a CT of <10 are also unreliable and are excluded 
from further analysis.  There are several ways to analyze qPCR data and the 
inclusion of internal controls in our assay helps control for variation of sample 
input.  The pre-miR array includes a U6 control primer, which is often used as a 
reference gene to normalize CT values from different samples. This normalized 
value to referred to as the delta CT value (dCT).  Results are often graphed as 
the raw CT, the dCT value or can be further analyzed to standardized values.   
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 In Figure A1, analysis of the full pre-microRNA array of four different 
samples from a timecourse experiment is presented in heat map format.  The 
relative expression of each pre-microRNA is shown and three major, distinct 
clusters emerged.  The majority of pre-miRs analyzed underwent small, 
insignificant changes as expected (Fig. A1a).  However, a small portion of pre-
microRNAs were significantly decreased (Fig. A1b) or increased dramatically 
(Fig. A1c) throughout the timecourse experiment.  Levels of expression of each 
pre-microRNA were normalized to the 0h timepoint (sample 1) as a baseline 
level.  In some instances, you may note that some of the clustered pre-
microRNAs also cluster together in the heatmap analysis (ex: let-7a, Fig. A1b).  
Depending on the experiment, clusters may emerge that are dependent on viral 
infection, cell type specific expression of pre-microRNAs or pre-miRs that are 
regulated by a common molecule or signaling pathway. 
 The pre-microRNA assay that we have developed also includes a number 
of known viral pre-microRNAs and genes encoded by Kaposi’s Sarcoma-
associated Herpesvirus (KSHV) and Epstein Barr Virus (EBV) in addition to the 
human pre-miRs.  These can be used as positive or negative controls, depending 
on the cell line and viral status of the samples used.  In Figure A2, the average 
CTs from a KSHV-negative sample run in quadruplicate are shown.  Importantly, 
KSHV LANA was not detected in this sample by the highly sensitive qPCR array.  
However, U6 --our internal control and let-7a --a highly expressed human pre-
microRNA, were expressed at detectable levels.  Finally, as expected, the 
negative control of PCR-grade water did not yield a qPCR product.   
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 Another indicator of a successful qPCR run is a good melting curve 
analysis, which can give insight into potential contamination in samples. To 
establish a melting temperature, the plate is heated slowly after the PCR is 
complete.  As the DNA strands separate, SYBR green is released, and 
fluorescence signal decreases. The temperature at which this drop occurs is 
graphed, and is known as the samples melting temperature.  Depending on the 
DNA sequence, samples melt at different temperatures from each other and from 
the water negative control, which should not have a melting temperature since no 
DNA is present initially.  The PCR products from each primer pair should melt at 
similar temperatures.  For example, Figure A3 shows a melting curve analysis for 
two different primers using the same sample in duplicate.  It is clear that the 
melting temperature is different for the two primer pairs but the sample is melting 
at the exact same temperature for each replicate.  Signs of a bad or potentially 
contaminated sample may include several melting peaks, suggesting the 
presence of two different sources of input.   
 
 
DISCUSSION 
qPCR is a highly sensitive assay that can be used to compare gene 
expression levels between samples in a study, as well as to determine positivity 
in the case of viruses (O’Hara et al., 2009).  The benefit of setting up qPCR 
arrays is the ability to run many primers (in our case, 186 primer pairs) for each 
sample in a short period of time.  Using a pipetting robot such as the Tecan 
Freedom Evo, the amount of time required to set an experiment up can be further 
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reduced, and the accuracy and consistency of the robot can reduce and 
eliminate pipetting errors (Fregeau et al., 2008).  Here we demonstrate how to 
use a Tecan Freedom Evo to set up a microRNA array, as well as an alternative 
method using a Matrix Electronic Multichannel Pipette, which can be 
implemented for labs who don’t have access to a pipetting robot.  qPCR arrays 
are also beneficial because all genes can be normalized to a single set of 
reference genes run on the same plate, reducing costs and number of reactions.   
 As mentioned, there are several key features that are necessary when 
designing such an array.  Since all samples on the PCR plate will be run at 
identical conditions, it is critical to design primers that function at the same 
temperatures and settings, or some primer pairs will fail.  When designing 
primers, the sequences should always be checked by BLAST search to ensure 
that homology to your gene of interest and no other genes.   
 When running the array, it is critical that the environment is sterile and free 
of PCR contaminants that may result in false positives.  If possible, PCR should 
be set up in a sterile work hood or a separate clean room, where PCR products 
are never worked with.  Benches should be washed with Eliminase, water, and 
ethanol, and subjected to UV light for at least an hour after the run is complete  
(Bustin et al., 2009).  
 The benefit of this technique is that this same strategy is applicable for 
any set of genes to be profiled by simply replacing the miRNA array with an array 
containing a different primer pair set.  Our lab currently contains arrays for pre- 
miRNAs, KSHV, EBV, p53, and NFkB  - all of which can be run in an identical 
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method to those shown.  The flexibility of this assay allows our lab to perform 
high-throughput gene profiling rapidly and reliably for any primer pairs that we 
wish to screen for.  
 Here, we described using cDNA from KSHV-positive cell lines to profile 
miRNA expression levels upon activation over a period of time. In addition to 
characterizing cell lines, the array can also be used to analyze clinical samples.  
Following RNA isolation, cDNA synthesis can be performed, and the cDNA can 
be run using this array to characterize gene expression. This can be useful in 
determining viral positivity, or gene expression profiles to further characterize 
which genes are up-regulated in samples from infected patients.   
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TABLES AND FIGURES 
 
 
TABLE A1: Specific reagents and equipment 
 
Name of Reagent Company Catalogue 
number 
Comments 
Freedom Evo 150 Tecan 30017587  
Matrix Electronic 
Multichannel 
Pipette 
Thermo Scientific 2001-MTX (or any comparable Thermo 
Scientific multichannel that can 
pipette the volumes described 
above) 
Matrix Integrity 
Filter Tips, Sterile 
Thermo Scientific 7435 (or comparable tip for 
multichannel used) 
Lightcycler® 480 
SYBR Green 1 
Master 
Roche 04 707 516 001  
Lightcycler® 480 
Instrument II 
Roche 05015243001 384-well version 
Lightcycler® 480 
Multiwell Plate 
384, white 
Roche 04729749001  
LightCycler® 480 
Sealing Foil 
Roche 04729757001  
LightCycler® 480 
Multiple Plate 
Analysis Software 
Roche 05075122001  
Eliminase 
Decontaminant 
Decon 
Laboratories 
04-355-31  
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FIGURE A1: Pre-microRNA signatures emerge through profiling using 
a novel qPCR-based array. 
 
 
The average deltaCT U6 was calculated and standardized values were loaded 
into ArrayMinerTM Software, yielding 3 distinct clusters displayed as heatmaps. 
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(A) Pre-microRNAs with small changes in expression are shown.  Pre-
microRNAs whose levels were significantly decreased (B) or increased (C) are 
also shown. Blue corresponds to lower levels of expression while red represents 
increased expression levels.  
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FIGURE A2: Inclusion of internal controls in the qPCR based pre-
miRNA array 
 
 
 
The raw CT values for 3 different genes and a no- template control are shown. 
U6 is used as an internal control while PCR H2O serves as our negative control.  
Let7a is a microRNA normally expressed in many different cell types while KSHV 
LANA can be used as either a positive or negative control, based on the viral 
status of the cell line or tissue being used.   
 
 147 
FIGURE A3: Melting peak analysis of pre-microRNA primers and lack 
of sample contamination 
 
 
 
Melting curves were obtained using the TM calling analysis on the LightCycler 
software.  Two different primers (Primer A and Primer B) for the same sample 
run in duplicate are shown. The melting temperature for each primer is distinct. 
However, the sample has only one peak for each replicate, demonstrating the 
lack of sample contamination.  
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